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ABSTRACT
Background: Interleukin (IL) 6 signals in two pathways. In classical signalling, 
essential in antimicrobial defence and tissue regeneration, IL6 binds the membrane-
bound IL6 receptor (IL6R) which associates with the signal transducing receptor 
gp130. The pro-inflammatory effects of IL6 on the other hand, are governed by 
IL6 trans-signalling via the binary complex of IL6 and the soluble IL6R (sIL6R) 
through gp130 binding. The binary IL6:sIL6R complex is neutralised by the  soluble 
gp130 (sgp130) thereby preventing IL6 trans-signalling. IL6 trans-signalling is 
associated with chronic inflammatory conditions.
Overarching aim: To analyse the association of IL6 trans-signalling, estimated 
by a ratio between the active binary IL6:sIL6R complex and the inactive ternary 
IL6:sIL6R:sgp130 complex (the binary/ternary complex ratio [B/T ratio]), with 
the risk of cardiovascular event (CVE) and investigate the presence of IL6 signal-
ling in manifest atherosclerosis. 
Methods and results 
Study I: In a prospective cohort of 60-year-olds (60YO) without prevalent cardiovas-
cular disease (CVD) (n=3645), the binary IL6:sIL6R and ternary IL6:sIL6R:sgp130 
complex levels, expressed in nanomole/litre, were derived from baseline serum 
concentrations of IL6, sIL6R, and sgp130. IL6 trans-signalling was estimated by 
a ratio between the pro-inflammatory binary complex and the inactivated ternary 
complex, the B/T ratio. Cox regression was used to assess the risk of CVE (myo-
cardial infarction, angina pectoris and ischaemic stroke), expressed as hazard ratio 
(HR) with 95% confidence interval (CI), associated with increasing circulating 
levels of IL6, sIL6R, sgp130 and with the B/T ratio, the latter analysed both as a 
continuous variable and dichotomised at the median. Estimates were adjusted for 
the common cardiovascular risk factors. The discriminatory ability of the B/T ratio 
as predictor was assessed by the area under the curve (AUC) and net reclassifica-
tion index (NRI) in relation to the Framingham risk score (FRS) and IL6. 
The B/T ratio >median associates with increased CVE risk (adjusted HR 1.44, 
95% CI 1.21–1.72). The prediction of CVE improved by adding the B/T ratio to 
the FRS and IL6 and 10% of subjects were re-classified.
Study II: In the 60YO cohort, CVE risk associated with B/T ratio >median was 
investigated in subjects with low-intermediate cardiovascular risk defined by LDL 
≤ / >4.0 mmol/L or according to the FRS. The difference in time to event (years; 
95% CI) was analysed with quantile regression. In secondary analyses, risk of 
coronary and cerebrovascular events and time to event was analysed. Biological 
interaction between LDL and B/T ratio was estimated on the additive scale and the 
incremental discriminatory value of the B/T ratio with FRS and IL6 was compared 
in subjects with LDL≤ and >4.0 mmol/L. 
B/T ratio was associated with an increased risk of CVE primarily the LDL≤4.0 
group (adjusted HR 1.59; 95% CI 1.24-2.05) but also in FRS <20% 10-year risk. 
The highest risk and earliest events were seen for ischemic stroke. No interaction 
between LDL and the B/T ratio was seen and the B/T ratio improved prediction 
in the LDL ≤4.0 group. 
Study III: Carotid artery plaques were obtained during endarterectomy in 
patients with high-grade carotid artery stenosis in the Biobank of Karolinska 
Endarterectomies (BiKE) study. Oligoprimers were designed to selectively amplify 
IL6R, sIL6R, GP130 and sGP130 genes. Using cDNA reverse transcribed from 
RNA extracted from plaques quantitative real time-PCR was performed and the 
relative difference in expression between groups was estimated using the ∆CT 
method (n=78). Correlations between plaque gene expression and plasma levels 
were tested using Spearman’s correlation coefficient. 
Gene expression of IL6, IL6R, sIL6R, GP130 and sGP130 were detected in all 
plaques. A pattern of differential plaque expression depending on disease severity 
was seen as well as a trend towards positive correlations between IL6 and sIL6R 
plaque expression and corresponding protein levels in the circulation.
Study IV: In the 60YO cohort, risk of incident ischemic stroke associated with the 
B/T ratio >median was analysed using Cox regression and stratified by prevalent 
or incident atrial fibrillation (AF). In secondary analyses, the risk of first-time 
diagnosis of AF associated with the B/T ratio >median was analysed. 
The B/T ratio was associated with ischemic stroke risk only in subjects without 
AF (adjusted HR 1.49; 95% CI 1.08-2.06). In addition, no association between the 
B/T ratio and risk of first-ever AF (HR 0.96; 95% CI 0.75-1.24) was seen albeit 
an indication of an association with IL6. 
Conclusions: Pro-inflammatory IL6 trans-signalling, estimated by B/T ratio>median 
mirroring a relative excess of the binary complex (IL6:sIL6R) in relation to the 
inactive ternary complex (IL6:sIL6R:sgp130), is associated with an increased risk 
of future CVE in subjects without prevalent CVD, primarily in individuals at low-
intermediate risk of CVE. IL6 signalling is present in carotid artery plaques and 
the B/T ratio is associated with an increased risk of atherothrombotic ischemic 
stroke and early stroke events albeit no association was established for ischemic 
stroke in relation to AF or for AF per se.
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11 BACKGROUND
1.1 Cardiovascular diseases: epidemiological notes
Improved public health and advances in medical care have succeeded in reducing 
cardiovascular disease (CVD) mortality and the age-standardised death rate has 
fallen during the past 30 years in high-income countries and to some extent in 
middle-income countries (1). Nevertheless, CVD is the leading cause of death in 
the world accounting for 15 million deaths in 2016 according to the World Health 
Organisation (2). 
Myocardial infarction (MI) is the first and stroke the second most common cause 
of death worldwide (1, 2). In Sweden, cardiovascular mortality constitutes 33% 
of all deaths (3). In 2017, there were 26 000 cases of MI and nearly 21 000 cases 
of stroke in 2018 (4, 5). The vast majority of strokes (87%) are ischemic and 21% 
have atrial fibrillation (AF) as a potential cause of cerebral emboli (4). In line 
with the trend in high-income countries, numbers of acute MI and stroke have 
decreased in Sweden (5, 6). 
Increased awareness of cardiovascular health in the population has resulted in a 
decline in the number of smokers, attention is paid to avoid a sedentary lifestyle, 
to promote physical activity and to eat a balanced diet. Together with effective 
secondary preventive treatments, these factors have contributed to improve CVD 
statistics albeit challenges such as increasing incidence of obesity and diabetes 
mellitus type 2, known cardiovascular risk factors, remain to be conquered (7). 
We stand at the breaking point of the next paradigm in CVD prevention. In the 
last decade, the understanding of CVD risk has begun to shift from a primary-
secondary preventive approach to more individualised prediction with the aim 
to assess individual cardiovascular risk on a continuous risk spectrum (8). To 
increase the ability to predict and cure CVD and reduce the burden of CVD, we 
need novel biomarkers able to identify individuals at risk, above and beyond the 
known cardiovascular risk factors and risk scores. 
1.2 Inflammation in atherosclerosis
Atherosclerosis is the hallmark of coronary and cerebrovascular disease and inflam-
mation the soil in which atherosclerotic lesions arise. In the coronary and carotid 
vascular beds, atherosclerotic plaques are the cause underlying coronary artery 
disease (CAD) and ischemic stroke, albeit the mechanisms might be somewhat 
different (9, 10). A large bulk of evidence supports the notion that a low-grade 
chronic inflammation in atherosclerosis contributes to and interacts with the tradi-
tional cardiovascular risk factors; hypertension, diabetes mellitus, hyperlipidaemia, 
2obesity, sedentary lifestyle and smoking, in determining the cardiovascular risk in 
men and women (11). Recently, a large clinical trial demonstrated that in patients 
with stable CAD, treating inflammation reduces the risk of future cardiovascular 
events (CVE) (12). This strongly suggests that inflammation partly explains the 
cardiovascular risk remaining when treating or adjusting for the traditional cardio-
vascular risk factors, the so called residual inflammatory risk (13). 
Much effort has been put into the quest to find both novel inflammatory targets to 
improve treatment of atherosclerosis related CVD and inflammatory biomarkers 
able to ameliorate our ability to identify individuals at risk of future CVE. 
In this thesis, we analyse the predictive capacity of a novel inflammatory biomarker, 
assessing interleukin 6 (IL6) trans-signalling activity, and its role in predicting the 
risk of CAD and ischemic stroke above and beyond the known cardiovascular risk 
factors. We also discuss if targeting IL6 trans-signalling might represent a novel 
treatment moiety for CVD.
1.2.1 The central axis of inflammation in atherosclerosis
The inflammatory response in atherosclerosis is mainly driven by the central axis 
of inflammation: the interleukin (IL)1β-IL6-C-reactive protein (CRP) pathway 
(Figure 1). IL6 signals through two signalling systems: the so called IL6 classi-
cal signalling with CRP as one of the end-products (Figure 1, left hand side) and 
the so called IL6 trans-signalling (Figure 1, right hand side). 
Figure 1. Schematic representation of the IL1b-IL6-CRP pathway
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Figure 1. NLRP3=(NOD [nucleotide oligomerisation domain]-LRR [leucine rich repeat]-
and PYD [pyrin domain]-containing protein 3) inflammasome, CHIP=clonal hematopoiesis 
of Indeterminate Potential, CRP=C-reactive protein. Ziegler 2020 (unpublished).
31.2.1.1	 Interleukin	1β	
Interleukin 1β (IL1β) is the upstream regulator of the central axis of inflammation. 
In atherosclerotic plaques, IL1β synthesis is tightly regulated: pro-IL1β, the 
inactive IL1β precursor, is produced intra-cellularly and activated via proteolytic 
 cleavage by the protease Caspase-1 which in turn needs to be activated by the 
NLRP3 (NOD [nucleotide oligomerisation domain]-LRR [leucine rich repeat]-and 
PYD [pyrin domain]-containing protein 3) inflammasome (14). Inflammasomes 
are intracellular multimolecular signalling complexes possessing the ability to acti-
vate innate immune system responses (15). The NLRP3 inflammasome requires a 
two step activation in which the first step induces the transcription of the NLRP3 
constituents as well as the pro-IL1β and the second step activates the assembly of 
the inflammasome and subsequently the cleavage of pro-IL1β into the active IL1β 
(14). Cholesterol crystals leaking out of dying foam cells in the necrotic core of 
atherosclerotic plaques, through inflammasome activation, elicit IL1β release which 
is associated with plaque progression in in vitro studies (16-18). The  rigorously 
regulated activation of the NLRP3 can however be impaired due to mutations and 
give rise to auto-inflammatory disorders, rare diseases characterised by recurrent 
fever and local inflammation in organs such as the skin and joints (19). 
Another mechanism known to regulate IL1β production is the clonal haemat-
opoiesis of indeterminate potential (CHIP), a precancerous condition well known 
from studies of haematological malignancies, in which somatic mutations allow 
competitive growth and clonal expansion of stem cells (20). This phenomenon, 
associated with aging and present in 10% of individuals >70 years, has recently 
been demonstrated to increase the risk of cardiovascular mortality (21, 22). The 
CHIP mutations are associated with a pro-inflammatory phenotype and TET2, 
a transcriptional regulator affecting the NLRP3 inflammasome mediated IL1β 
secretion and enhancing atherosclerotic lesions progression, is among the most 
frequent CHIP mutations (23, 24).
Hence, biological data indicate that IL1β may represent a potential target for treat-
ment. This hypothesis was tested and confirmed by the results of the CANTOS 
study, a double blind randomised clinical trial demonstrating that treatment with 
canakinumab, a human monoclonal antibody against IL1β , was associated with a 
15% relative CVE risk reduction in patients with chronic CAD (12). IL1β is diffi-
cult to measure and clinical studies analysing IL1β inhibition such as the CANTOS 
study, have measured IL6 and/or CRP to assess activity in the pathway instead.
1.2.1.2 C- reactive protein
CRP, a nonglycosylated pentraxin circulating in the blood arranged in a pentamer, 
was first described in the 1930ies and later found to be an acute phase reactant. In 
4the late nineties, it was demonstrated that levels of high sensitivity CRP (hsCRP) 
were elevated decades before the first ever CVE (25, 26). Based on these results 
P.M. Ridker and collegues demonstrated that adding CRP and parental history of 
CVD to the Framingham risk score (FRS), improved risk classification  measures 
and individuals at low cardiovascular risk were correctly re-classified as at 
intermediate risk (27, 28). A large metanalysis led by the Emerging Risk Factor 
Consortium, supported this notion showing a robust association between increased 
hsCRP and risk of future CVE (29). By then, the JUPITER trial had demonstrated 
that reducing cholesterol levels with a cholesterol lowering drug (rosuvastatin) also 
had beneficial anti-inflammatory effects and reduced the rate of first ever MI and 
stroke by half (30). The study supported the concept of “dual targets” i.e. achieving 
the greatest effect on CVD when both low-density lipoprotein (LDL) cholesterol 
and CRP are significantly lowered, a finding supported also by the PROVE IT 
and the A to Z clinical trials (31, 32). On the other hand, two population-based 
Mendelian randomisation studies challenged the notion of a causal association of 
CRP with CVD and found that genetic variants associated with CRP levels were 
not associated with the risk of CAD (33, 34).
The discovery of a monomeric CRP (mCRP) molecule is relatively new (35). The 
mCRP stems from the pentameric CRP when it, under certain conditions such as 
in contact with activated platelets, dissociates into a singular pentraxin monomers 
(36). The mCRP has been demonstrated in atherosclerotic plaques and recently 
mCRP was found to circulate in the blood stream after conversion from pentameric 
to monomeric form on microparticles in patients with MI (36, 37). The discovery 
of mCRP and its association with atherosclerosis can potentially shed a light on the 
complex association between CRP and CVD. At present, the existing data  support 
the use of hsCRP as a biomarker for cardiovascular risk but, given the fact that 
causality of the association between CRP and CVD risk is not proven, CRP is unfit 
as an interventional target for treament and prevention (33, 34). 
1.3 Interleukin 6
In 1968, the discovery that T cells were interacting with B cell antibody synthe-
sis led to the hypothesis that signalling molecules derived from T cells were able 
to stimulate B cells (38). One of these molecules was interleukin 6 (IL6), a 184 
amino acids long protein possessing pleiotropic properties which initially confused 
researchers into believing they were carried out by different signalling molecules. 
IL6, in fact, has anti-inflammatory as well as pro-inflammatory properties depending 
on which IL6 signalling pathway is active as will be descibed in detail below (39). 
5IL6 belongs to the IL6 family of cytokines (including e.g. IL11, ciliary neurotrophic 
factor, leukaemia inhibitory factor, oncostatin M, cardiotrophin 1, cardiotrophin-
like cytokine, and IL27) that share similar biological properties (40). In particular, 
they all signal via receptor complexes consisting of an individual ligand binding 
α-receptor and a shared signal transducing β-receptor, glycoprotein 130 (gp130) 
(41). IL6 is synthesised by a large spectrum of cells: hepatocytes, cardiomyocytes, 
lipocytes, immune cells including monocytes and macrophages and vascular wall 
cells such as endothelial cells, smooth muscle cells (SMC) and fibroblasts (42). 
Once released in the circulation, IL6 circulates in extremely low concentrations, 
as reported in Table 1. The half-life of IL6 depends on the physiological and 
pathophysiological condition in the human body and ranges from <10 minutes to 
2-15 hours (43-45). 
Table 1. Circulating levels of IL6, sIL6R and sgp130 and dissociation constants 
for complex binding in IL6 classical and trans-signalling
sIL6R (30–70 ng/mL) IL6R
IL6 (1–5 pg/mL) 1 nM 1 nM
sgp130 (200–400 ng/mL) gp130
IL6:(s)IL6R 10 pM 10 pM
The circulating serum concentrations of IL6, sIL6R and sgp130 are reported within  parenthesis 
in g/mL while dissociation constants for the binding of IL6 to the (s)IL6R and of the binary 
IL6:sIL6R complex to (s)gp130 are reported in molar=M.
1.3.1 Interleukin 6 signalling 
IL6 signalling occurs through the binding of IL6 to the ligand binding IL6 recep-
tor (IL6R) also known as IL6Rα or glycoprotein (gp) 80. The IL6R exists in two 
isoforms: a membrane-bound form and a soluble one (sIL6R). IL6 binds to IL6R 
with the same affinity regardless of the receptor isoform (Table 1) (46, 47). 
To elicit the intracellular signalling cascade, the IL6:(s)IL6R complex associates 
with the signal transducing co-receptor gp130 (also known as IL6Rβ or CD130). 
Neither IL6 nor IL6R can bind gp130 on its own, thus the binary complex of IL6 
and (s)IL6R is needed for the binding to gp130 (48). The IL6:(s)IL6R binds the 
signal transducing β-receptor gp130 with high affinity as seen in Table 1 (49). 
This affinity gradient, with lower affinity between the ligand and the ligand bind-
ing receptor (IL6:(s)IL6R) and higher affinity in the binding of the binary IL6:(s)
IL6R complex to the signal transducing receptor gp130, is shared with the other 
cytokines in the IL6 cytokine family (46, 50). 
6The expression of the membrane-bound IL6R is limited to hepatocytes, hemat-
opoietic cells, immune cells and endothelial cells whereas gp130 is expressed on 
all human cells (51, 52).
The signalling moiety mediated by the binding of IL6:IL6R to gp130 is known as 
IL6 classical signalling and exists only on cells expressing the membrane-bound 
IL6R (53). The IL6 signal mediated by the IL6:sIL6R binding to the gp130 is 
known as IL6 trans-signalling. The circulating IL6 in complex with sIL6R enables 
IL6 trans-signalling to impact all cells of the body given the ubiquitous expres-
sion of gp130 (53). 
1.3.2 Interleukin 6 signalling: intracellular mediators
Upon IL6 binding the (s)IL6R, the subsequent association with gp130 induces a 
homodimerisation of gp130 and the intracellular recruitment of the signal transduc-
ing tyrosine kinases, Janus kinases (JAK) which phosphorylates tyrosine residues 
on the gp130 receptor. The IL6 triggered JAK activation can follow either the 
JAK-SHP-2 (Src homology region 2 domain-containing phosphatase-2)-mitogen–
activated protein kinase (MAPK) pathway or the JAK-STAT3 (signal transducer 
and activator of transcription 3) pathway (54) (Figure 2). In the latter, the most 
common IL6 induced pathway, JAK transduces the cytokine-mediated signal by 
docking STAT3 which after translocation into the nucleus binds the promoter region 
of target genes (41, 55). Upon binding to IL6R and gp30, the complex bound IL6 
is rapidly internalised and eventually degraded while remaining IL6R on the cell 
membrane are down-regulated thus desensitising the cell to IL6 (49, 55). A special 
case of IL6 signalling is the endosomal intracellular autocrine signalling seen in 
immune system dendritic cells and hepatocytes (56, 57). 
The suppressor of cytokine signalling (SOCS) family members 1 and 3 regulate 
the intracellular IL6 signalling via feedback regulation (58). The primary  regulator, 
SOCS3 inhibits JAK activity when binding JAK and gp130 simultaneously (59). 
The importance of SOCS3 regulation is demonstrated by the observation that 
mice genetically engineered to have a defective binding of SOCS3 to gp130/JAK 
develop severe inflammatory conditions and cancer (59). In addition, IL6 gene 
expression is regulated by RNA binding proteins which either prolong or terminate 
expression. Imbalance in this regulation may result in overexpression of IL6 as 
seen in cancer and autoimmune diseases (60).
7Figure 2. Schematic illustration of the intracellular IL6 signalling pathways
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Figure 2. MAPK=mitogen–activated protein kinase, SHP-2= Src homology region 2 
domain-containing phosphatase-2, STAT3= signal transducer and activator of  transcription 
3, JAK=janus kinase, P=phosphate, SOCS1 and SOCS3=suppressor of cytokine signal-
ling 1 and 3. 
Ziegler 2020 (unpublished)
1.3.3 Interleukin 6 classical signalling
The receptors of the IL6 classical pathway are depicted in Figure 3. 
Overall the IL6 classical signalling possesses important physiological properties in 
the immune system and in cell regeneration. In the immune system, IL6 classical 
signalling is pivotal in the innate immune reactions i.e. the direct nonspecific cell 
mediated part of the immune response e.g. attracting monocytes and stimulating 
their differentiation into macrophages (61). In addition, IL6 classical signalling is 
active in the acquired antibody mediated adaptive immune system being a regulator 
of B cell transition to antibody-producing plasma cells and T cell differentiation 
(62, 63). IL6 stimulates the development of the pro-inflammatory T helper cell 
(Th) 17 while inhibiting the differentiation of anti-inflammatory regulatory T cells 
(Treg), an effect also mediated by IL6 trans-signalling (64, 65). 
8IL6 classical signalling is the main mediator of the acute phase reaction in the liver. 
The main effects are increasing levels of CRP, fibrinogen, haptoglobin, and serum 
amyloid A and simultaneously decreasing albumin and transferrin production (66). 
As a consequence of the central role for IL6 in immunity, IL6 deficiency under-
mines the antibacterial defence in the immune system thus increasing susceptibility 
to infectious diseases. Mutations in genes encoding JAK and STAT3, such as in 
autosomal dominant hyper-IgE syndrome, result in Th17 deficiency with recurrent 
infections, primarily pneumonia (67, 68). In addition, when inhibiting IL1β with 
canakinumab the incidence of severe infections augmented (12).
When IL6, on the other hand, is produced in excess, such as in the inherited 
Castleman’s syndrome, an imbalance between pro-inflammatory Th17 cells and 
anti-inflammatory Treg cells are inhibited with accompanying inflammation, 
autoimmunity, lymphadenopathy, and hyperglobulinemia as a result (60, 69). 
Moreover, experimental and clinical data point to a crucial role for IL6 as a media-
tor of antibody mediated tissue and organ transplant rejections (70). 
IL6 classical signalling also exerts anti-inflammatory effects by stimulating the 
secretion of the IL1 receptor antagonist thus dampening signalling through the 
IL1β-IL6-CRP pathway (66). Moreover, IL6 classical signalling possesses regenera-
tive, cytoprotective and wound healing properties in different organs and tissues 
such as the nervous and musculoskeletal system (40, 71-74). 
Figure 3. Schematic presentation of IL6 classical and trans-signalling
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Figure 3. Ziegler 2020 (unpublished)
91.3.4 Interleukin 6 trans-signalling
IL6 trans-signalling is the IL6 signalling pathway responsible for the pro- inflammatory 
effects of IL6. In IL6 trans-signalling, IL6 binds the soluble isoform of the IL6R, 
the sIL6R (39). Subsequently the binary IL6:sIL6R complex binds the membrane-
bound gp130 to elicit the intracellular signal cascade (Figure 2). This signalling 
moiety is tightly regulated to avoid uncontrolled systemic inflammation: a soluble 
isoform of gp130 (sgp130) functions as a natural inhibitor of IL6 trans-signalling 
by neutralising the excess of the binary IL6:sIL6R complex (75) (Figure 3). 
1.3.4.1 The soluble interleukin 6 receptor
The sIL6R is produced mainly through shedding, i.e. limited proteolytic cleavage 
of the membrane-bound IL6R by the metalloproteinases ADAM17 and ADAM10 
(76, 77). The receptor is cleaved at the juxtamembrane region (78). In acute inflam-
mation, shedding of IL6R on neutrophils by ADAM 17 is elicited by inflammation 
associated factors such as apoptosis, bacterial toxins, CRP and IL8 (76, 79, 80). 
Levels of sIL6R are halved in IL6 knockout mice indicating the presence of an 
autocrine feedback loop of IL6 on IL6R expression (81). 
Circulating levels of sIL6R are genetically regulated. A single nucleotide poly-
morphism (SNP) within the extracellular domain of the IL6R gene (rs2228145-AC) 
causes an amino-acid change (Asp358Ala) that favours shedding and is associated 
with a two-fold increase in sIL6R levels (82). The presence of the C-allele is not 
associated with the traditional cardiovascular risk factors but it has been consist-
ently shown that for every copy of the C-allele inherited, the sIL6R concentration 
increased on average by 34% (83). Homozygotes for the rare allele at rs4537545-
CT, a SNP in full linkage disequilibrium with rs2228145, exhibited doubled sIL6R 
concentrations as compared to homozygotes for the common allele (84). Moreover, 
the same study demonstrated that the IL6R SNP analysed accounted for 20% of 
the sIL6R variance in the circulation. A small proportion of the circulating sIL6R 
is produced by alternative splicing, a transcriptional mechanism that results in the 
trans-membrane part of the receptor not being translated (85-89). 
1.3.4.2 The soluble glycoprotein 130
The sgp130 is the natural circulating antagonist of IL6 trans-signalling. The inhibitory 
properties of sgp130 consist in the ability to competitively sequester and  neutralise 
the binary IL6:sIL6R complex (Figure 3). The binary IL6:sIL6R complex binds 
sgp130 with the same affinity as gp130 (90) (Table 1). The inactivated ternary 
IL6:sIL6R:sgp130 complex is a hexameric consisting of two molecules each of IL6, 
sIL6R and sgp130 (91). The addition of sgp130 to the binary complex prevents dock-
ing to gp130 hence inhibiting IL6 trans-signalling (90) (Figure 3). Little is known 
about the regulation and the physiological role of circulating  levels of sgp130. The 
majority of the circulating sgp130 is produced by alternative  splicing of the gene 
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encoding the membrane-bound protein, GP130 (92). The factors inducing sgp130 
production through alternative splicing are unknown. We have recently shown 
that about 26 genetic variants contribute to determine sgp130 circulating levels 
in serum and explain 11% of the variance (93). 
Three different sgp130 isoforms have been detected: the full length sgp130, 
sgp130-RAPS (rheumatoid arthritis [RA] associated peptide) and sgp130-E10 
(94-96). While sgp130-RAPS is a 50 kilo Dalton (kDa) molecule, the other two 
isoforms are 90-110 kDa in size. The sgp130-RAPS was originally discovered 
in RA patients and is the only isoform verified by Western blot (94, 95). The 
sgp130-E10 isoform on the other hand accounts merely for 1-2% of circulating 
sgp130 (95). The isoform most efficient in inhibiting IL6 trans-signalling is the full 
length sgp130 with inhibition executed in an autocrine fashion in cells secreting 
protective sgp130 (92, 93). In addition, in an in vitro experimental setting, it was 
demon strated that monocytes expressed the full-length sgp130 albeit the expres-
sion disappeared upon their differentiation into macrophages (92). 
1.3.4.3 The interleukin 6 trans-signalling buffer 
The pro-inflammatory IL6 trans-signalling pathway contains an intrinsic buffer 
that prevents an uncontrolled systemic inflammatory reaction driven by the active 
IL6:sIL6R. 
As shown in Table 1, a concentration gradient exists among the three circulating 
components of the IL6 trans-signalling with increasing concentrations from IL6, 
sIL6R to sgp130 (96, 97). In mild/chronic inflammatory states, IL6 can increase 
its concentration up to 150 ng/mL while it can further increase a million-fold, 
exceeding sgp130 levels with potential systemic IL6 trans-signalling, during 
systemic inflammation/infections such as sepsis (98, 99). The soluble receptor 
concentrations on the other hand do not change as much and will normally not 
increase more than 2-5 fold during inflammation (99). Thus, under physiological 
circumstances sIL6R, being in excessive concentration, will bind the majority of 
the circulating IL6 (75, 100). Likewise, sgp130 circulates in excess in relation to 
IL6:sIL6R and this concentration gradient together with the high affinity for sgp130, 
leads to a rapid formation of a ternary inactive complex (90) (Table 1). Being the 
antagonist of IL6 trans-signalling one would expect sgp130 to play a leading role 
in the buffer system, albeit sgp130 is incapable of inhibiting IL6 trans-signalling 
without sIL6R. Hence, the capacity of the buffer is decided rather by the amount 
of sIL6R than sgp130 as the latter is always in molar excess of sIL6R, and IL6 
only in extreme conditions can outnumber both (54, 98). The swift formation of 
the ternary IL6:sIL6R:sgp130 complex triggered by the sgp130 concentration 
gradient in the presence of a binary IL6:sIL6R complex leads to the subsequent 
formation of new binary complexes maintaining the balance between free and 
bound IL6 (75). 
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Increasing the sgp130 concentration beyond the physiological concentration 
gradient will speed up the elimination of binary complexes through ternary com-
plex formation and subsequently drive the formation of new binary complexes 
hence decreasing the amount of free IL6. At very high concentrations of sgp130, 
classical signalling can be blocked due to lack of unbound IL6 (75, 90, 92). In 
case of a simultaneous increase in sIL6R concentration, the depletion of free IL6 
will accelerate even further demonstrating how increasing sIL6R concentrations 
potentiate the buffer (100, 101). In physiological conditions, there will however 
always exist a small proportion free IL6 enabling classical and trans-signalling to 
occur simultaneously (75, 101). 
1.4 Interleukin 6 trans-signalling in inflammatory 
diseases
IL6 trans-signalling mediates the transition from acute to chronic inflammation. 
Signs of active IL6 trans-signalling is demonstrated in several chronic inflamma-
tory conditions such as inflammatory bowel disease (IBD) (102, 103), RA (104, 
105), glomerulonephritis (106), cancer (107-113), metabolic syndrome (114) 
and periodontitis (115). In RA, high levels of sIL6R have been associated with a 
more severe disease and a monoclonal IL6R antibody, tocilizumab is approved 
for patients not responding to standard treatment (116, 117). The efficacy of treat-
ment with tocilizumab in RA indicates that the IL6 system plays an important role 
in the progression of this chronic inflammatory disorder (118). Treatment with 
tocilizumab affects both the IL6 classical and IL6 trans-signalling inferring side 
effects from immune system inhibition with increased incidence of infections (119). 
In addition, increased levels of lipids are seen with tocilizumab treatment. This is 
however, a sign of successful dampening of chronic inflammation as cholesterol 
is used as fuel in the energy consuming inflammatory processes and thus lipids 
are known to be lower in patients with chronic inflammatory conditions (120). It 
has not been elucidated if this change in cholesterol levels has a pro-atherogenic 
effect. On the other side, the risk of CVD is reduced in the presence of an effective 
anti-inflammatory treatment (121). For instance, it was demonstrated in women 
with RA that treatment with tocilizumab improved two subclinical measures of 
atherosclerosis; the endothelial dependent vasorelaxation and aortic stiffness (122). 
In the search for an immunomodulatory agent to target IL6 trans-signalling, a 
recombinant form of the antagonist sgp130, sgp130Fc was developed (90). The 
anti-inflammatory effect of sgp130 is supported by experimental data: in the air-
pouch model, using transgenic mice overexpressing sgp130Fc, IL6 trans-signalling 
was effectively inhibited as was the recruitment of mononuclear cells (123). The 
sgp130Fc is currently tested in phase II clinical trial of IBD (124).
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1.5 Interleukin 6 trans-signalling in atherosclerosis
IL6 is mainly synthesised by endothelial cells and SMC in the vascular wall (125). 
In Figure 4, a few key events of the inflammatory process in atherosclerosis and 
the role of IL6 trans-signalling are depicted. IL6 trans-signalling participates in the 
transition from acute to chronic inflammation in the vascular wall and contributes 
to a sustained inflammatory reaction. 
The inflammatory response in atherosclerosis starts with the endothelial cell activa-
tion and subsequent loss of the endothelial barrier, secretion of pro-inflammatory 
interleukins, expression of adhesion molecules and progression towards a pro-
thrombotic state (126). These initial steps are governed by the cells of the innate 
immune system, monocyte recruitment being one of the earliest features (9, 127). 
The eliciting factors of atherosclerosis are manifold albeit one of the most central 
events is the binding and retention of LDL by proteoglycans in the sub-endothelial 
space (128). In this hyperlipidaemic setting, monocytes are transformed into a 
more pro-inflammatory cell type secreting pro-inflammatory cytokines such as 
IL1 and IL6 (127). In an in vitro co-culture study, interaction between vascular 
SMC and monocytes, by means of the pro-inflammatory cytokines IL1, TNF-α 
and IL6, induced production and secretion of IL6 and monocyte chemoattractant 
protein 1 (MCP-1) (129). 
Taking these findings into the vascular wall it could be speculated that migrating 
monocytes coming into contact with resident vascular SMC result in increased 
IL6 and MCP-1 levels further attracting monocyte to the area and stimulating 
the continued inflammatory process. Monocytes eventually migrate through the 
disrupted endothelial layer into the sub-intimal space where they are transformed 
into macrophages stimulated by macrophage colony stimulating factor. Modified 
by lipases and proteases, ensnared LDL molecules aggregate, are increasingly 
bound by the surrounding proteoglycans and are then further modified by factors 
such as reactive oxygen species resulting in the development of oxidised LDL 
(130, 131). Macrophages engulf the oxidised LDL and are transformed into foam 
cells expressing scavenger receptors on the cell membrane. SMC migrated from 
the media into the sub-intimal space can also give rise to foam cells after prolif-
eration and together with macrophage derived foam cells they accumulate in the 
atherosclerotic plaque (129, 132). Foam cells in the intima die through apoptosis 
releasing cholesterol crystals forming the central necrotic core of the atherosclerotic 
plaque. The leakage of cholesterol crystals is one of the ignitors for the IL1β-IL6-
CRP pathway as previously described.
The sIL6R is mainly produced by proteolytic cleavage from the cell membrane 
of local neutrophils stimulated by IL8 and other inflammation associated factors 
hence increasing concentrations of sIL6R and the assembly of binary IL6:sIL6R 
complexes (79, 80). IL6 trans-signalling driven by the binary complex enhances 
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MCP-1 and IL8 secretion from inflamed vascular endothelium thereby promot-
ing a neutrophil – monocyte shift and further augmenting IL6 trans-signalling 
by stimulating continued shedding of sIL6R and increased IL6 production (79, 
129, 133, 134). Moreover, IL6 trans-signalling activates vascular SMC and via 
up-regulation of their cell surface gp130 expression subsequently enhances IL6 
secretion constituting a positive feedback loop resulting in MCP-1 secretion and 
SMC proliferation (135-137).
Figure 4. Schematic representation of key events in the inflammatory response 
in atherosclerosis and the role of IL6 trans-signalling
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Ziegler 2020 (unpublished)
In addition, thrombin-activated endothelium has been shown to drive the IL6 trans-
signalling neutrophil-monocyte transition in vitro (79). Apart from demonstrating 
one potential mechanism behind IL6 trans-signalling in atherogenesis, this study 
also provided a possible link between inflammation and thrombosis in the interplay 
between thrombin, IL6 trans-signalling and chronic inflammation in the vessel wall. 
Analysing the effects of IL6 trans-signalling in experimental murine models of 
atherosclerosis, injecting recombinant IL6 resulted in enhanced fatty lesions after 
6-21 weeks in one model, while inhibiting IL6 trans-signalling by injecting recom-
binant sgp130Fc dampened progression of aortic plaques and to some extent even 
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induced regression of plaques in another (138, 139). More recently in abdominal 
aortic aneurysm murine models, injecting sgp130Fc increased survival and reduced 
aortic ruptures, while treatment with an IL6R antibody (blocking both IL6 classi-
cal and trans-signalling) had no effect on aneurysm rupture (140). 
1.6 Interleukin 6 trans-signalling in coronary artery 
disease
IL6R is the only gene regulating inflammation whose genetic variants have been 
causally associated with CAD risk. In a genome-wide association study (GWAS) 
designed to investigate the association of genetic loci with the risk of CAD, an 
IL6R variant (rs4537545-CT) was associated with increased CAD risk and in addi-
tion elevated CRP levels (33). This finding was strengthened by the results from 
two meta-analyses demonstrating that another IL6R variant (rs7529229), in strong 
linkage disequilibrium with the variant increasing the shedding rate of the IL6R, 
was associated with higher serum levels of sIL6R and with a decreased risk of 
CAD (141, 142). Further verification of the association was presented in a GWAS 
designed to identify novel loci associated with CAD risk and the IL6R was one 
of the 46 loci reaching genome-wide significance which together explain around 
10% of CAD heritability (143). Of importance, the direct association between 
sIL6R levels and CAD risk was not analysed in the above-mentioned studies. 
Instead, to explain the association of rs7529229 with increased sIL6R levels and 
reduced CAD risk, the results were compared to that of tocilizumab treatment. 
The interpretation from the authors was that the lower CAD risk in the presence of 
high sIL6R levels could be explained by the effect of the IL6R shedding mutation: 
an increased cleavage of the membrane-bound IL6R caused a decreased IL6R 
expression and a reduced IL6 classical signalling as observed with tocilizumab 
treatment (144). Notwithstanding, the finding that the same genetic variant was 
associated with both increased sIL6R levels and decreased CAD risk is not con-
sistent with the evidence from experimental studies discussed so far and is not 
in line with the current understanding that IL6 trans-signalling, mainly regulated 
translationally and post-translationally, is the pathway driving IL6 associated CVD 
risk. One possible explanation is instead that higher levels of sIL6R potentiate the 
IL6 trans-signalling buffer system as sIL6R is the key for the antagonist sgp130 
to incapacitate the IL6:sIL6R complex (145, 146). Thus, the increased levels of 
sIL6R are not per se associated with a decreased risk of CAD, but possibly with 
increased circulating levels of the inactive ternary (IL6:sIL6R:sgp130) complex 
which in turn might have been associated with a decreased risk of CAD in the 
meta-analyses discussed.
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Several clinical studies have demonstrated the value of IL6 as risk predictor of 
cardiovascular risk (147). Analysing the association of the soluble IL6 receptors 
with the risk of CAD, studies on sIL6R are relatively unanimous in showing det-
rimental effects associated with high sIL6R levels while studies on sgp130 have 
on the other side demonstrated controversial findings. 
High sIL6R levels have been observed in the acute phase of MI (148, 149). 
Moreover, increased circulating sIL6R levels have been associated with the  severity 
of myocardial injury, with a reduced myocardial reperfusion after percutaneous 
coronary intervention and with an increased risk of all cause and cardiovascular 
mortality in patients with ST-elevation MI (148, 150, 151). In all of these studies, 
sIL6R blood samples were collected in the acute phase of the CVE thus mirroring 
an acute inflammatory state. In an attempt to investigate the association between 
sIL6R and CVE in a steady state condition, we measured sIL6R and sgp130 levels 
three months after the event in a population-based MI case control study with the 
result that high sIL6R levels were associated with an increased risk of MI while 
high sgp130 levels seemed to be able to counteract this detrimental effect (152). 
On the contrary, circulating levels of sgp130 have been associated with CAD and 
mortality albeit with controversial results. In patients with stable CAD, plasma 
levels of IL6 were increased and sgp130 levels decreased while sIL6R did not 
 differ compared to healthy controls (153). In addition, sgp130 levels were nega-
tively correlated with the number of diseased coronary arteries in cases. Similarly, 
patients with stable or unstable CAD undergoing coronary angiography displayed 
significantly lower sgp130 levels compared to healthy controls (138). In the same 
study, patients with unstable CAD and multivessel disease had even lower sgp130 
plasma levels in relation to single-vessel diseased and in all unstable CAD patients 
there was a pattern of augmented IL6 and reduced sIL6R levels. High levels of 
sgp130 were also associated with increased cardiac morbidity and mortality in 
elderly patients with heart failure of ischemic origin (154). Overall there is a contro-
versy between the data on sgp130 from the experimental and observational studies.
One possible explanation is that it is hard to interpret the impact of sgp130 as well 
as the association of IL6R with the CAD risk on its own as the entire signalling 
system relies on the relative concentrations of the three biomarkers. In particular, 
the function of sgp130 is tightly dependent on the presence, availability and con-
centration of the binary IL6:sIL6R complex.
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1.7 Interleukin 6 trans-signalling in cerebrovascular 
disease
Ischemic cerebrovascular disease consists of a group of conditions with similar 
neurological symptoms but with a plethora of underlying pathophysiological 
processes. Categorising ischemic stroke subtypes based on aetiology, the Trial of 
Org 10172 in Acute Stroke Treatment (TOAST) defined subgroups of ischemic 
stroke: large vessel disease, small vessel disease, cardioembolism, stroke of other 
determined aetiology and stroke of undetermined aetiology (155). In this thesis, the 
focus will be on the association of IL6 trans-signalling with large vessel cerebro-
vascular diseases and with cardioembolism.
1.7.1 Interleukin 6 trans-signalling in large vessel 
 cerebrovascular disease 
The function of IL6 signalling in the ischemic brain is not entirely evident as 
conflicting results with both detrimental pro-inflammatory and regenerative and 
anti-inflammatory effects have been demonstrated in experimental and clinical 
studies (156).
In experimental models, increased IL6 levels are induced by injury to the carotid 
artery (157). Similarly, acute cerebrovascular occlusion is associated with elevated 
levels of IL6 in clinical studies (158-160). In addition, high serum IL6 associates 
with asymptomatic carotid artery stenosis and signs of unstable carotid plaques 
(161-164). Within the first days after an ischemic stroke, circulating IL6 increases 
and correlates with infarct size, early neurologic deterioration and long-term poor 
outcome (156, 158). Furthermore, expression of IL6 in neurons, astrocytes and glia 
is enhanced in the sub-acute phase of stroke (159, 165, 166). In the acute phase of 
cerebral ischemia, IL6 expression and secretion is increased with elevated con-
centrations found in the cerebrospinal fluid greater than circulating serum levels, 
indicating local IL6 production in the central nervous system (CNS) (159, 167). 
In an experimental model of transient middle cerebral artery occlusion in rats, 
expression of IL6 was concentrated to neurons in the cerebral cortex in areas sur-
rounding the infarction from 3 hours up to 7 days after the exposure (165). 
Investigating the ambivalent properties of IL6 in CNS, a neuroprotective effect 
was demonstrated when injecting recombinant IL6 into the cerebral ventricles of 
rats (166, 168). However, no difference in the infarct size or neurologic function 
between IL6 knockout mice and wildtype littermates was seen 24 h after induced 
cerebral ischemia (169). 
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Current knowledge of the effect of IL6 signalling proposes that IL6 classical signal-
ling is neuroprotective (170, 171). Exploring the effects of the IL6 trans-signalling 
pathway in relation to classical IL6 signalling in the CNS, the distribution of IL6R 
is crucial. IL6R mRNA has been quantified in microglia, astrocytes and neurons 
albeit the IL6R protein has solely been detected in microglia (172). As microglia 
express the IL6R it can be subject to classical IL6 signalling whereas neurons and 
astrocytes only respond to the binary IL6:sIL6R complex indicating that they lack 
the IL6R, the membrane-bound receptor (173, 174). 
IL6 trans-signalling is proposed to be responsible for neuronal degeneration in 
cerebral ischemia. In a transgenic murine model with astrocytes overexpressing 
IL6, localised neuroinflammation and secondary neuronal deficits were demon-
strated (175). In an attempt to explore IL6 trans-signalling as the cause of neuro-
inflammation the same research group developed a bigenic mouse with the same 
CNS-restricted production of IL6 but with the addition of localised sgp130Fc 
production and showed mitigated effects of inflammation (176). Moreover, in a 
model of lipopolysaccharide-induced neuroinflammation, intraventricular injec-
tions of sgp130 accelerated the recovery in mice (177). 
Clinical studies on IL6 trans-signalling and ischemic stroke are extremely scarce. 
Research on sIL6R is inconsistent, with two case control studies displaying no dif-
ference in sIL6R levels between ischemic stroke cases and controls whereas levels 
of IL6 were higher in cases (160, 178). Moreover, in subjects with manifest CVD, 
sIL6R showed no association with recurrent CVE while in post-MI patients, high 
circulating levels of sIL6R were associated with increased risk of recurrent CVE 
(151, 179). Levels of sgp130 have been demonstrated to be transiently reduced 
after stroke and to correlate positively with blood pressure and carotid intima 
media thickness in stroke patients (160, 180). 
The current understanding is thus that classical IL6 signalling has a regenerative 
role in the CNS while neuronal degeneration is governed by IL6 trans-signalling. 
1.7.2 Interleukin 6 trans-signalling in cardioembolic 
 cerebrovascular disease
AF is a common arrhythmia associated with an increased risk of ischemic stroke 
(181). The exact mechanism is not fully understood but the current understanding 
is based on the interaction of several mechanisms such as those in Virchow’s triad 
(182, 183). From the research underlying the CHADS-VASc score, the most widely 
used risk score to evaluate stroke risk in AF, it is known that certain factors such 
as age, sex, hypertension, diabetes mellitus, heart failure, prior ischemic cerebral 
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event, prevalent CVD, increase the risk of thromboembolism in AF (184). In spite 
of the prothrombotic and pro-inflammatory state described in AF, scores such as 
the CHADS-VASc do not take components of inflammatory pathways or coagu-
lation cascade into account (185). The association between circulating IL6 levels 
and risk of AF and secondary thromboembolic events has been investigated in a 
handful of studies describing increased levels of IL6 in AF patients compared to 
healthy controls (185-187). IL6 levels are positively correlated with the presence 
and duration of AF in addition to the diameter of the left atrium (188). Furthermore, 
multiple studies have demonstrated an association between IL6 serum levels with 
the occurrence of AF after cardiac surgery/intervention (186, 189-192). Increased 
levels of IL6 have also been associated with a prothrombotic state and increased 
risk of thromboembolic events in AF patients (186). On the other hand, in a case 
control study, patients with AF had high IL6 levels but without an association with 
markers of endothelial activation or active thrombogenesis and treatment with oral 
anticoagulant therapy left IL6 levels unchanged (193). IL6 in general has been 
quite thoroughly studied in relation to AF, thromboembolism and stroke, while 
the IL6 trans-signalling pathway specifically has not. 
In two Mendelian randomisation studies analysing the association of the IL6R with 
AF and secondary ischemic stroke, a causal association was demonstrated (194, 
195). In addition, the more recent of the two studies proposed that the increased risk 
of cardioembolic stroke associated with the IL6R was accounted for by AF (195). 
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2 AIMS OF THE THESIS
The overarching aim of this thesis is to analyse the association of the circulating 
IL6 trans-signalling, estimated by a ratio between the active binary IL6:sIL6R 
complex and the inactive ternary IL6:sIL6R:sgp130 complex (the binary/ternary 
complex ratio [B/T ratio]), with the risk of CVE and to shed a light on the role of 
IL6 trans-signalling in clinically manifest atherosclerosis. 
Aim of each study within the thesis:
Study I To analyse the association between the B/T ratio and the risk of future 
CVE in a population-based study of 60-year-old men and women from 
Stockholm.
Study II To analyse the association between the B/T ratio and the risk of future 
CVE in individuals at low-intermediate risk of CVE. 
Study III To investigate if IL6 and the membrane-bound and soluble IL6R 
and gp130 genes are expressed in carotid artery plaques of patients 
undergoing carotid endarterectomy due to carotid artery stenosis.
Study IV To analyse the association between the B/T ratio and the risk of future 
ischemic stroke in relation to atrial fibrillation.
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3 METHODS 
3.1 The cohort of 60-year-old men and women from 
Stockholm
3.1.1 Study population in Study I, II, IV
Results from Study I, II and IV were derived from the cohort of 60-year-old men 
and women from Stockholm (60YO). The 60YO is a prospective population-based 
cohort designed to identify novel cardiovascular risk factors and biomarkers. 
From August 1997 to March 1999, every third man and woman born between 
July 1st 1937 and June 30th 1938 residing in the Stockholm County were ran-
domly selected from the Swedish Population Register (n=5460, 2779 men and 
2681 women) and received a letter of invitation to participate in a cardiovascular 
health screening study. The letter contained a complete description of the study 
and stated clearly that participation was voluntary. In addition, recipients were 
informed that results from the health screening would be interpreted by a physi-
cian and in case of pathological findings participants would be given appropriate 
medical advice. Recipients were asked to contact a study nurse to state whether 
they were interested in participating or not. Participants who accepted to enter 
the study gave the study nurse their oral consent which was then recorded in the 
study case report form. Written consent forms were not mandatory in Sweden at 
the initiation of the study. Each reply was documented and those who accepted 
participation received an appointment for the health screening and were sent the 
comprehensive study questionnaire while those who were not interested were with-
drawn from the list of eligible study participants. With a 77.5% positive response 
rate, 4232 participants were included in the study (2193 women and 2039 men). 
At the baseline visit, participants met with a study nurse and underwent a physi-
cal examination including height and weight measurements and blood pressure 
measured after 5 min of rest in a sitting position using an automatic device 
(HEM 711; Omron Health Care, Bannockburn, IL) with the mean of two values 
calculated. A wider cuff was used if the participant had an upper arm >32 cm in 
circumference. Each participant had an electrocardiogram (ECG) recorded and 
blood samples were drawn after overnight fasting from an antecubital vein. Plasma, 
serum and whole blood were separated, immediately frozen at −80 °C and stored 
in a biobank. Certain biochemical tests were run in parallel with the screening 
including fasting levels of serum lipids analysed with enzymatic methods (Bayer 
Diagnostics, Tarrytown, NY, USA) and serum glucose measured with an enzy-
matic colorimetric test (Bayer Diagnostics). LDL cholesterol was estimated using 
the Friedewald method.
21
Demographic data as well as participants’ anamnestic records on lifestyle habits, 
details on current and previous diseases and medication were obtained from the 
self-administered questionnaire sent home to participants upon acceptance to par-
ticipate. The answers in the questionnaire were checked together with the study 
doctor at the baseline visit.
For all analyses presented in this thesis, participants with an incomplete study 
questionnaire (n=122), prior CVD i.e. either self-reported or diagnosis code of 
CVD in the national registers before enrolment (n=369) or lacking serum samples 
for the measurement of IL6, sIL6R and sgp130 (n=96) were excluded, leaving 
3645 study participants as seen in the flow chart in Figure 5. 
Figure 5. Flow chart of the inclusion/exclusion criteria in the cohort of 
 60-year-old men and women from Stockholm adopted in Studies I, II and IV
Figure 5. Ziegler 2020 (unpublished)
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3.1.2 Outcome ascertainment in Study I, II, IV
To extract the outcome diagnoses, the personal identification number of each 
study participant was linked on a regular basis to the mandatory national Swedish 
 registers; The Swedish National Inpatient Register and The National Cause of 
Death Register. The Swedish National Inpatient Register started in 1964 and 
reached complete (99%) national coverage of all somatic and psychiatric hospital 
discharge diagnoses in Sweden in 1987 with a positive predictive value on diag-
noses from this register of 85-95% on average (196). The Inpatient Register does 
not contain diagnoses from primary care. The National Cause of Death Register 
with national coverage since 1952 contains date of death and associated primary 
cause of death with accompanying diagnoses recorded on all deceased in Sweden 
and Swedes deceased abroad (197). 
In Study I and II, the primary endpoint was first time incident fatal and non-fatal 
composite CVE recorded until December 31st 2014 in the national registers. Subjects 
with the following diagnosis codes according to the International Classification 
of Diseases 10th revision (ICD-10) were categorised as a case: I21 MI; I20 and 
I25 coronary heart disease; I46 cardiac arrest with/without successful resuscita-
tion; and I63 ischaemic stroke. Fatal CVE was defined as sudden cardiac death 
or death with the underlying diagnosis codes I21 (MI) or I63 (ischaemic stroke). 
Solely main diagnoses were recorded. After exclusions had been applied, the study 
population consisted of 546 incident cases of CVE until December 31st 2014. From 
the study population, 21 subjects were additionally excluded since they had been 
inaccurately classified as cases with one of the following ICD-10 diagnosis codes: 
I259 chronic ischemic heart disease (n=4) as this implies prevalent CAD; I252 old 
MI (n=1) as this diagnosis similarly implies manifest CAD or at least introduces 
uncertainty of the exact time of the first presentation of CAD; I652 carotid artery 
stenosis (n=8) as this diagnosis not necessarily entails an ischemic stroke; and 
I649 stroke, not specified as haemorrhage or infarction (n=8) since the nature of 
the cerebrovascular event could not be ascertained. After the final exclusions had 
been executed, 525 cases of CVE remained in the data set for analyses.
In Study II, the secondary endpoints were either fatal or non-fatal ischaemic stroke 
(ICD-10: I63) or coronary event (ICD-10: I20, I21, I25, I46), respectively. In the 
analysis of incident ischaemic stroke, cases of incident CAD events (n=361) were 
excluded and similarly cases of ischaemic stroke (n=164) were excluded when 
analysing the risk of incident CAD.
In Study IV, the primary endpoint was fatal and non-fatal ischeamic stroke (I63). 
In this study, cases of CVE until December 31st 2017 had been ascertained in 
national registers. Using the same exclusion and inclusion criteria as in Study I 
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and II, the study population consisted of 655 incident CVE. In line with exclusions 
performed in secondary analyses in Study II, individuals with an incident CAD 
event during follow-up were excluded (n=433). In addition, subjects inaccurately 
categorised as incident ischemic stroke with ICD-10 diagnosis codes I649 (stroke, 
not specified as haemorrhage or infarction) or I652 (carotid artery stenosis) were 
excluded (n=19). The total number of incident ischemic strokes after inaccurate 
diagnoses had been excluded was 203. 
Incident AF was the secondary endpoint in Study IV. Both main and secondary 
diagnoses of AF (ICD-10: I48) were ascertained from registers. To estimate the 
association of IL6 trans-signalling with the risk of AF, individuals with prevalent 
AF at baseline (n=29) were excluded i.e. those with either self-reported AF, AF 
on the baseline ECG or the ICD-10 diagnosis code I48 in national registers before 
inclusion. In addition, cases of incident ischemic stroke (n=203) were excluded. 
Given that the B/T ratio was associated with the risk of incident CVE in Study I-II 
(Figure 11, Table 4), keeping incident cases of ischemic stroke in the referent 
group might have attenuated a potential association with AF. 
3.1.3 Biomarker measurement in Study I, II, III and IV
The IL6, sIL6R and sgp130 were measured in serum in Study I, II and IV and in 
plasma in Study III. 
Serum and plasma concentrations of IL6 and sIL6R were measured with Meso 
Scale Discovery Human Cytokine Assay (Gaithersburg, MD, USA). To measure 
IL6, samples were diluted 1:2 and to measure sIL6R diluted 1:50. Concentrations 
were derived from an experimental standard curve and expressed in pg/mL (IL6) 
and ng/mL (sIL6R). The lower limit of detection for IL6 was 0.06 pg/mL and for 
sIL6R 0.1 ng/mL. 
Serum and plasma sgp130 was measured by means of an assay development kit 
(#DY228) provided by R&D Systems (R&D systems Minneapolis, MN, USA) 
and samples were diluted 1:100. The experiment was performed in 96-well plates 
coated with diluted capture antibody (4.0 lg/mL) incubated overnight at room 
temperature. After blocking further binding with 2% bovine serum albumin the 
diluted serum/plasma sample was added. After 2 hours incubation, detection anti-
body (0.08 lg/mL), Streptavidin and substrate colour reagent were added stepwise. 
Ultimately, the plate was read in a microplate reader (Tecan, Infinite F200) set to a 
wavelength of 450 nm. Concentrations of sgp130 expressed in ng/mL were derived 
from the standard curve. A recombinant sgp130 with a known concentration of 
5 ng/mL was used to validate the concentrations estimated in the experiment. The 
lower limit of detection for sgp130 in our experimental condition was 1.69 ng/mL. 
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All measurements were performed according to the protocol from the assay manu-
facturer and the researcher setting up the plate templates for all experiments was 
blind to study participants’ case/referent status. 
The variability of concentration values within an assay, the intra-assay variability 
and the variability of concentration values between assays, the inter-assay  variability 
were calculated with the following formula: Coefficient of variation = duplicate 
standard deviation/duplicate mean.
The intra-assay variability was 6.3% for IL6 with 478 duplicates, 4.7% for sIL6R 
with 284 duplicates, and 4.5% for sgp130 with 395 duplicates. The data presented 
represent the average of the coefficients of variation of duplicate samples run in 
the same assay. 
The inter-assay variability was 3.5% for IL6, 7.5% for sIL6R, and 6.0% for sgp130 
and represents the average of the coefficient of variation of duplicate samples 
analysed in 32 sequential plates using the same formula as for intra-assay vari-
ability presented above.
The recommended threshold is 15% for mean intra-assay coefficient of varia-
tion and 18% for mean inter-assay variation for IL6 and sIL6R according to the 
manufacturer. No limits for intra- and inter-assay variability were suggested by the 
manufacturer for sgp130, albeit in prior studies an intra-assay variability <10–11% 
and inter-assay variability <10–16% have been reported (198, 199). 
3.1.4 Calculating the binary and ternary IL6 complexes in 
Study I, II, IV
The constituents of the IL6 complexes interact on a molar basis in the circulation. 
The molar (M) concentration, i.e. moles per litre of IL6, sIL6R, and sgp130 for each 
individual was calculated by dividing the serum concentration (ng/mL) by their 
respective molecular weights (IL6 23.7 kDa, sIL6R 50 kDa, and sgp130 100 kDa). 
The nanomolar (nM) concentration of the binary and ternary complex was then 
estimated using the formulas presented by Müller-Newen et al. (75, 101). 
[IL6:sIL6R]=0.5[sIL6R]i+0.5[IL6]i+0.5KD1−0.5([sIL6R]i2+[IL6]i2+2[IL6]iKD1+KD12)0.5
[IL6:sIL6R:sgp130]=0.5[sgp130]i+0.5[IL6:sIL6R]i+0.5KD2−0.5([sgp130]
i2+[IL6:sIL6R]i2+2[IL6:sIL6R]iKD2+KD22)0.5
The [IL6]i, [sIL6R]i, and [sgp130]i were substituted with their respective nM 
serum concentrations. The dissociation constant values; binary complex KD1 = 0.5 
and ternary complex KD2 = 0.05 nM, were deducted from the original analysis of 
Müller-Newen and colleagues (75). To ascertain that the association between the 
IL6 complexes and the outcome would be valid in case of the dissociation constants 
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used being inadequate, the relative amount of the binary and ternary complexes 
replacing KD1 and KD2 with values ten times higher and ten times lower was cal-
culated using the same formula.
3.1.5 Ethics in Study I, II, IV
The 60YO was designed and conducted in accordance with the Helsinki Declaration. 
The study, including the procedure with oral consent documented by the study 
nurse, was approved by the Regional Ethics Review Board at Karolinska Institutet 
in Stockholm in the original application in 1996 (reference number 96-398) and 
in renewed applications addressing continued and extended research (reference 
numbers 99-306, 03-100 and 03-115, 16/205-31/2).
3.2 The Biobank of Karolinska Endarterectomies
3.2.1 Study population in Study III
Results from Study III were derived from the Biobank of Karolinska Endarterectomies 
(BiKE) cohort. The BiKE study, is a real-world clinical study analysing large  vessel 
cerebrovascular disease by including patients amenable for carotid  endarterectomy 
(CEA) due to a high-grade carotid artery stenosis according to the North American 
Symptomatic Carotid Endarterectomy Trial (NASCET) criteria (200). Patients about 
to undergo CEA at the Department of Vascular Surgery, Karolinska University 
Hospital or the Section for Vascular Surgery at the Department of Surgery, Söder-
sjukhuset Hospital, Stockholm, Sweden were sequentially enrolled in the BiKE 
study in 2002-2007. Exclusion criteria were: extensive neurological deficits or 
large cerebral infarcts as the risk of surgery would outweigh the  benefits and diag-
nosis of atrial fibrillation since this diagnosis possibly implicates a cardioembolic 
source of embolism rather than from the carotid artery. 
Patient clinical data, including history of diseases, chronic diagnoses, ongoing 
medical treatment, life style habits, were obtained on admission to hospital. Blood 
samples and carotid plaques were amassed at surgery. Under local anaesthesia CEA 
was performed and the plaque retrieved cut in half in the most stenotic region. 
The proximal portion of the plaque was directly frozen at −80 °C and kept in the 
BiKE study biobank together with the blood samples.
The analysis performed in this thesis was analysed in a plaque profiling subset 
(n=97) of the BiKE cohort (201). In the flow chart in Figure 6, the exclusions 
performed in the present analysis of the BiKE study are shown. Participants were 
excluded from analyses due to incomplete clinical data (n=4), lack of samples for 
the semi-quantitative real time polymerase chain reaction (semi-qRT-PCR) (n=11) 
or a standard deviation >0.5 in the semi-qRT-PCR (n=4). 
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Participants with contralateral cerebral deficit symptoms < 6 months preceding 
CEA were categorised as symptomatic and those without symptoms of neurologi-
cal deficit or symptoms ≥ 6 months prior to CEA as asymptomatic. For the latter, 
CEA indication was based on the ACST (Asymptomatic Carotid Surgery Trial) 
results (202). 
Symptoms of neurological deficit, potentially mirroring plaque instability, were 
either transient (<24 hours) as in transitory ischemic attack (TIA) or amaurosis 
fugax (transient retinal ischemia) or permanent as in ischemic stroke. Out of the 
78 patients in the present analysis, 53 were defined as symptomatic and 25 as 
asymptomatic.
Figure 6. Flow chart of study population from a BiKE subset in Study III
Figure 6. Ziegler 2020 (unpublished)
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3.2.2 Gene expression analyses in Study III
Gene expression levels of IL6 had been previously analysed in the same samples and 
expression (log2) had been estimated by Affymetrix HGU133plus2 micro arrays (201). 
The microarray dataset is available from Gene Expression Omnibus (GSE21545).
3.2.2.1 Oligoprimer design 
Oligoprimers were designed to selectively amplify and thereby quantify the expres-
sion of IL6R, sIL6R, GP130 and sGP130-RAPS (sGP130) in carotid artery plaques 
by Bruna Gigante (BG) and Jasmine Lundqvist (JL). For the membrane-bound 
(IL6R; GP130) and soluble (sIL6R; sGP130-RAPS) receptors, oligoprimers were 
designed to selectively amplify each receptor individually. 
The IL6R cDNA sequence NM_000565.4 (base pairs [bp] 1261-1560) together 
with the oligoprimers designed to amplify the two IL6 receptors, IL6R and sIL6R 
are presented in Figure 7. The sIL6R lacks a 94-bp fragment coding the IL6R 
transmembrane (TM) region as a result of alternative splicing. In the oligoprimer 
sequences designed to amplify sIL6R: the reverse primer spans across the splicing 
junction, while the IL6R reverse primer lies in the TM region.
Figure 7. Schematic representation of the IL6R cDNA and oligoprimer sequences 
chosen to amplify the IL6R and the sIL6R
1261 ACGAGGTGTC CACCCCCATG CAGGCACTTA CTACTAATAA AGACGATGAT AATATTCTCT
1321 TCAGAGATTC TGCAAATGCG ACAAGCCTCC CAGTGCAAGA TTCTTCTTCA GTACCACTGC
1381 CCACATTCCT GGTTGCTGGA GGGAGCCTGG CCTTCGGAAC GCTCCTCTGC ATTGCCATTG
1441 TTCTGAGGTT CAAGAAGACG TGGAAGCTGC GGGCTCTGAA GGAAGGCAAG ACAAGCATGC
1501 ATCCGCCGTA CTCTTTGGGG CAGCTGGTCC CGGAGAGGCC TCGACCCACC CCAGTGCTTG
Oligoprimer sequences Amplicon length (bp)
IL6R forward 5’-AGAGATTCTGCAAATGCGACAAG-3’ 133
IL6R reverse 5’-TCTTGAACCTCAGAACAATGGC-3’
sIL6R forward 5’-CCCATGCAGGCACTTACTACT-3’ 93
sIL6R reverse 5’-ACGTCTTCTTGAACCTGGGA-3’
Figure 7. Oligoprimers used to amplify the membrane-bound IL6R are written in red: the 
forward (bp 1323-1345) and the reverse primer (bp 1434-1455). The reverse primer lies in 
the sequence coding the TM domain (underlined). 
Oligoprimers used to amplify the sIL6R are written in bold black: the forward (bp 1274-
1294) and the reverse primer (bp 1348-1353 and 1448-1461). The reverse primer crosses 
the splicing junction and overlaps from bp 1448 to bp 1455 with the IL6R reverse primer 
(highlighted in bold cursive red). 
The oligoprimer sequences and amplicon length are reported in the table under the figure.
28
In Figure 8. GP130 cDNA sequences are represented schematically. 
Panel A shows the nucleotide sequence of the membrane-bound GP130 isoform 1 
(GenBank accession number: NM_002184.4 [bp 1251-1420]) and Panel B shows 
the soluble GP130 isoform 2 also known as sGP130-RAPS (NM_175767.3 
[bp 1201-1420]) (94, 203, 204). 
The soluble sgp130-RAPS is produced by alternative splicing of exon 9 (203): The 
alternative splicing results in a stop codon and creates a shorter protein lacking 
the TM domain (exon 15) (203). The only sgp130 isoforms verified by Western 
blot is sgp130-RAPS (95). 
Figure 8. Schematic representation of the GP130 cDNA and oligoprimer 
sequence (Panel A.) and of the sGP130-RAPS cDNA and oligoprimer 
sequence (Panel B.)
PANEL A.
1251 AAGATAGACC ATCTAAAGCA CCAAGTTTCT GGTATAAAAT GATCCATCC CATACTCAAG 
1311 GCTACAGAAC TGTACAACTC GTGTGGAAGA CATTGCCTCC TTTTGAAGCC AATGGAAAAA 
1371 TCTTGGATTA TGAAGTGACT CTCACAAGAT GGAAATCACA TTTACAAAAT TACACAGTTA 
PANEL B. 
1231AGCAAGTGGG ATCACCTATG AAGATAACAT TGCCTCCTTT TGAAGCCAAT GGAAAAATCT
1291 TGGATTATGA AGTGACTCTC ACAAGATGGA AATCACATTT ACAAAATTAC ACAGTTAATG
1351 CCACAAAACT GACAGTAAAT CTCACAAATG ATCGCTATCT AGCAACCCTA
Oligoprimer sequences Amplicon length (bp)
GP130 forward 5’-GATCCATCCCATACTCAAGG-3’ 112
GP130 reverse 5’-TCCATCTTGTGAGAGTCAC-3’
sGP130 forward 5’-ATAACATTGCCTCCTTTTGAAGCC-3’ 140
sGP130 reverse 5’-GCTAGATAGCGATCATTTGTGAG-3’
Figure 8. Panel A: Oligoprimers used to amplify the membrane-bound GP130 are  written 
in bold black: the forward (bp 1291-1311) and reverse primer (bp 1384-1403). The forward 
oligoprimer lies in the sequence coding exon 9 (underlined) with the donor and  acceptor 
sequences at the splicing junction (underlined in red). Alternative splicing of exon 9 results 
in the alternative GP130 transcript (reported in Panel B) which translates in the  soluble 
isoform sgp130-RAPS (sGP130). Panel B: Oligoprimers used to amplify the soluble 
gp130-RAPS (sGP130) are written in bold black: forward (bp 1254-1276) and reverse 
(1371-1393) oligoprimers. This isoform lacks exon 9 which is present in the membrane-
bound gp130. The forward oligoprimer spans the splicing junction (underlined in red). 
Oligoprimer sequences and amplicon length are reported in the table under the figure.
29
In preliminary experiments we tested four housekeeping genes, β-ACTIN, 
 glyceraldehyde 3-phosphate dehydrogenase (GADPH), β2-microglobulin and 
16S ribosomal-RNA. Two of them β-ACTIN and GAPDH were chosen since they 
could be successfully amplified together with the IL6R. The β-ACTIN oligoprimer 
was designed on cDNA sequence NM_001101 and the GADPH primer on cDNA 
sequence NM_002046. The oligoprimers were designed based on sequences 
extracted from GenBank and the sequences are shown in Table 2. 
Table 2. Oligonucleotide primers for housekeeping genes, β-ACTIN and GAPDH.
Gene Primer Sequence Amplicon length (bp)
b -ACTIN Forward 5’-GTGATGGACTCCGGTGACG-3′ 191
Reverse 5′-TTCTCCTTAATGTCACGCACGAT-3′
GAPDH Forward 5′-ACCCACTCCTCCACCTTTGAC-3′ 100
Reverse 5′-TGTTGCTGTAGCCAAATTCGTT-3′
3.2.2.2 Validation of oligoprimers 
Preliminary experiments were performed to validate the primer sequences. The 
cDNA was reverse transcribed by the QuantiTect Reverse Transcription Kit 
(QIAGEN GmbH, Hilden, Germany) from total RNA extracted from HepG2 cells. 
Polymerase chain reaction (PCR) was then performed for each of the primers set 
with 0.5 pmol/μl of forward and reverse primers, 0.02 U/μl Phusion DNA poly-
merase, 1X Phusion HF buffer, 200 pmol/μl dNTP, 0.5 ng/μl template cDNA in a 
20 μl reaction. The cycles used were 98 °C for 2 min, followed by 35 cycles at 98 
°C for 10 s and 60 °C for 30 s and 72 °C for 30 s. The PCR products were loaded 
on a 3% agarose gel with GelRed® Nucleic Acid Gel Stain (Biotium, Fremont, 
CA, USA). After gel electrophoresis and UV-examination, fragments were puri-
fied using the QIAquick Gel Extraction Kit (QIAGEN GmbH, Hilden, Germany). 
Amplification of PCR products was verified through sequencing at the KIGene 
core facility (Karolinska Institutet, Sweden). 
3.2.2.3  Probe design 
TaqMan probes were custom designed by Applied Biosystems (Thermo Fisher 
Scientific) to be compatible and selective for our oligoprimer/gene sequences. 
IL6 signalling receptors were made as minor groove binder probes and house-
keeping genes as QSY probes, so that two minor groove binder probes could be co-
amplified with the two housekeeping genes in one multiplex. Applied Biosystems 
manufactured a designed assay mix (containing primers and probes) for each IL6 
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receptor and for β-ACTIN and GAPDH. Applied Biosystems vouch that each assay 
has passed bioinformatic quality control and is predicted to be specific. Lastly, 
the assays are not predicted to interact with each other in a multiplex reaction.
As last step in the validation of the primers and probe sequence, cDNA at  different 
concentration (0.2-0.5 ng/microliter) was amplified as singleplex as well as in 
 multi plex in all assay combinations. From these experiments, an optimal oligo-
primer/probe concentration was derived. In the multiplex reaction, IL6R, sIL6R, 
GP130 and sGP130-RAPS were used at a concentration of 900 nM for each 
primer and mixed with 250 nM of probe while β-ACTIN and GAPDH were used 
at a concentration 225 nM for each primer and mixed with 62.5 nM probe.
3.2.2.4 Real time semi-quantitative PCR 
Total RNA (3.3 ng/ul) extracted from carotid endarterectomies was reverse tran-
scribed to cDNA using the QuantiTect Reverse Transcription Kit (QIAGEN GmbH, 
Hilden, Germany) and random primers as described previously (205). 
Five nanograms of cDNA was used for each semi-qRT-PCR reaction, which 
were run in duplicates, using the TaqMan Multiplex Master Mix on an Applied 
Biosystems 7500 Real-Time PCR system. The cycles used were 95 °C for 20 s, 
followed by 40 cycles at 95 °C for 3 s and 60 °C for 30 s. The genes were multi-
plexed in two sets. The first included IL6R,	sIL6R,	β-ACTIN and GAPDH, and 
the second GP130, sGP130-RAPS,	β-ACTIN and GAPDH. Oligoprimers/probe 
concentrations in each reaction are outlined above. 
JL and Kristian Dreij (KD), who ran the semi-qRT-PCR, were not aware of 
the symptomatic and asymptomatic status of the patients included in the study. 
Comparison of gene expression levels of IL6R, sIL6R, GP130 and sGP130-RAPS 
was quantified by the comparative cycle threshold (CT) method (206). The differ-
ence between the cycle threshold (CT) for each target gene and the average CT of 
the two housekeeping genes (∆CT) was calculated for every sample. Since gene 
expression is inversely related to the ∆CT threshold value, the negative ∆CT value 
was used in the analyses to facilitate interpretation of the results.
3.2.3 Ethics Study III
The BiKE study followed the Declaration of Helsinki guidelines with human 
 samples and clinical data collected with informed consent from patients. The 
study was approved by the Ethical Committee of North Stockholm (ethical permit 
numbers: 95-276/277; 01-199; 02-147; 2009/512-31/2). 
31
3.3 Statistical analyses
In all the four studies, continuous variables are presented as median with an 
interquartile range (IQR) while binary variables are presented as proportion or 
percentages. For all statistical analyses, the significance threshold for the p value 
was set at ≤0.05.
All statistical analyses were performed in Stata Corp. (Stata statistical software: 
Release 14. College Station, TX: StataCorp LP) except for Study I in which R 
(www.r-project.org) was used to analyse the association with natural cubic splines 
and in Study II, NRI was calculated using SAS version 9.4 (SAS Institutet, Cary, 
NC, USA).
3.3.1 Study I
To estimate the relative risk of future CVE associated with IL6 trans-signalling, a 
ratio between the binary and ternary IL6 complexes was calculated based on the 
estimated molar concentrations of each component as described above. 
The risk of CVE associated with the B/T ratio was assessed using Cox proportional 
hazards models expressing risk as hazard ratio (HR) with a 95% confidence interval 
(CI). In preliminary analyses, each of the IL6 trans-signalling components; IL6, 
sIL6R, and sgp130, serum levels were analysed using Cox models. The depend-
ent variable in all analyses was time to incident CVE while IL6, sIL6R, sgp130 
serum levels, and the B/T ratio were predictors. Censoring was done after the 
occurrence of first time CVE, death or at the end of follow-up which ever came 
first. Schoenfeld’s test was performed to test proportionality of hazards. 
To test for non-linear associations, the effect of each predictor (IL6, sIL6R, sgp130 
and the B/T ratio) on the response variable (time to CVE) was modelled by means 
of natural cubic splines. Modelling was performed using the statistical software R 
and the function ‘ns’ in the R package ‘splines’. A spline basis with four  internal 
knots at the empirical quantiles was chosen. As IL6, sIL6R, and the B/T ratio 
seemed to have a linear association with the time to CVE, they were modelled in 
a regression equation using a linear function and the CVE risk expressed as HR 
(95% CI) per unit increase in serum concentration. The association of sgp130 with 
the risk of CVE on the other hand did not appear to be linear. As the distribution 
of the B/T ratio in the study population displayed a narrow range of values (IQR 
1.55-1.62), the relative risk associated with 0.1 unit increase of the ratio was ana-
lysed in the regression model estimating the CVE risk with the B/T ratio expressed 
as a continuous variable.
As seen in the graph plotted from the natural cubic spline analysis of the B/T ratio 
as a continuous variable, there was a pattern of lower risk associated with the B/T 
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ratio <the median (B/T ratio 1.59) and increased risk >median hence the median 
was chosen as a cut-off the B/T ratio (Figure 11). To further test this assumption, 
the B/T ratio was categorised into three groups with the referent group including the 
median (40-60th percentiles = B/T ratio 1.57–1.60 under the assumption of KD1 = 
0.5 nmol/L and KD2 = 0.05 nmol/L) and the group with the assumed lowest risk due 
to a relative excess of the ternary complex (<40th percentile) and the group with the 
assumed highest risk due to a relative excess of the binary complex (>60th percen-
tile). The lowest and highest groups were additionally sub-divided with the absolute 
lowest value <20th percentile (B/T ratio 1.54) and the absolute highest value >80th 
percentile (B/T ratio 1.62). In the main analysis, the relative risk associated with 
the B/T ratio >the median was tested with the B/T ratio ≤ median as the reference.
All Cox regression analyses were modelled using a crude model and a model adjusted 
for confounders: sex (male/female reported in the questionnaire), hypertension (blood 
pressure >140/90 mmHg and/or treatment for hypertension and/or self-reported), 
diabetes mellitus (fasting glucose >7.0 and/or treatment for diabetes and/or self-
reported), hyperlipidaemia (fasting total serum cholesterol >5.0 and/or treatment 
for hyperlipidaemia and/or self-reported), smoking, and body mass index (BMI). 
In addition, in preliminary analyses estimates were adjusted for treatment with anti-
inflammatory agents (high dose aspirin, statins), or immunomodulatory drugs (oral 
glucocorticoids, Sulfasalazine, Olsalazine, Mesalazine, Azathioprine, Cyclosporine, 
Methotrexate) as stated in the questionnaire. 
To analyse the potential impact of missing values on the risk estimates, a complete-
case analysis was performed. The analysis showed that disparities in crude and 
adjusted risk estimates did not depend on missing values (data not shown). 
We finally tested if the B/T ratio was able to improve discrimination and re-clas-
sification measures. The area under the curve (AUC) with a 95% CI and the Net 
Reclassification Improvement (NRI) were calculated to estimate the incremental 
discriminatory value of the B/T ratio in predicting future CVE compared with the 
Framingham Risk Score (FRS) combined with IL6 by means of a published algo-
rithm (207). The FRS estimating 10-year CVE risk was categorised according to 
the 20% risk while IL6 was categorised in quartiles and the B/T ratio dichotomised 
at the median.
3.3.2 Study II
In the primary analysis, the risk of future CVE associated with the B/T ratio >the 
median was analysed stratified by baseline LDL cholesterol levels ≤ 4.0 and >4.0 
mmol/L. The 4.0 mmol/L cut-off was derived from the receiver-operating charac-
teristics (ROC) curve and the sensitivity and specificity for different cut-offs were 
tested (Figure 9).
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Figure 9. ROC curve for LDL-cholesterol as predictor of CVE
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Figure 9. Receiver Operating Characteristics (ROC) Curve of LDL as predictor of CVE 
in the 60YO.
Reproduced with permission from Ziegler et al, The predictive role of interleukin 6 trans-
signalling in middle-aged men and women at low-intermediate risk of cardiovascular events, 
European Journal of Preventive Cardiology. 2020;27:122-129 (Study II).
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The CVE risk associated with B/T ratio >median was in additional analyses esti-
mated in sub-groups of low LDL: LDL < 3.0 and ≥3.0–≤4.0 and in subjects at 
low (< 10%), intermediate (10-20%) and high (>20%) 10-year CVE risk according 
to the FRS classification (208). The risk factors included in the FRS are: sex, age, 
total cholesterol/HDL-cholesterol ratio, systolic blood pressure, smoking, diabetes 
mellitus, and hypertensive treatment.
Cox proportional hazards model was used to estimate CVE risk associated with 
the B/T ratio > median. Relative risk was expressed as HR with 95% CI and B/T 
ratio ≤ median was the reference group in all analyses. Schoenfeld’s test confirmed 
proportionality of hazards. 
All estimates of relative risk or time to event were analysed as a crude model and 
adjusted for the same cardiovascular risk factors as in Study I (sex, BMI, current 
smoking, hypertension and diabetes mellitus). In addition, to test for potential 
confounding, reported ongoing long-term lipid lowering (n= 126, out of which 72 
on statins) or immunomodulatory treatment (n=152) or aspirin in >250 mg doses 
(n=31) was added to the multivariable model. 
Differences in time to event between groups defined by the dichotomised B/T ratio 
and stratified by LDL levels were expressed in years (95% CI) and estimated using 
quantile regression for censored data, implemented with Laplace regression (209). 
This quantile regression method models any given percentile of survival or as in our 
analysis, failure e.g. the 10th percentile of failure (CVE), as a function of covari-
ates such as the B/T ratio. For example, the 10th percentile of failure is the point 
in time by which 10% of the cohort has had CVE. Since approximately 10% of the 
participants in our LDL stratified analysis had experienced CVE  during follow-up, 
we estimated the 5th and 10th percentiles of CVE. We then tested whether these 
two time points in subjects with a B/T ratio >median differed from that in those 
with lower B/T ratio levels after adjusting for the above-mentioned confounders.
In secondary analyses, the risk of CAD and ischaemic stroke in addition to time 
to CAD and ischaemic stroke associated with B/T ratio > median vs. ≤median 
was estimated in the two LDL groups (≤4.0 and >4.0). Incident CAD cases were 
excluded when analysing the risk of ischaemic stroke similarly as ischaemic stroke 
cases were excluded when analysing the risk of CAD events associated with the 
B/T ratio. 
With the close interaction between inflammation and cholesterol in atherosclero-
sis initiation and progression the effect of potential interaction between the B/T 
ratio and LDL levels on the risk of CVE was estimated by means of a model of 
biological interaction on an additive scale (210). We calculated the interaction 
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between LDL levels >4.0 mmol/L and B/T ratio >median through the estimation 
of the relative excess risk due to interaction (RERI), the attributable proportion 
(AP) and the synergy index (SI). The biological interaction assumes that if two 
factors are interacting, the risk associated with the presence of both is higher than 
the sum of the risk associated with each one of them. To model this interaction 
four exposure groups were defined according to LDL levels and the B/T ratio a: 
the reference group (LDL ≤4.0;B/T ratio ≤median), the group exposed to LDL >4.0 
but B/T ratio ≤median; the group exposed to B/T ratio >median but LDL ≤4.0; 
and finally the group exposed to LDL >4.0;B/T ratio >median. In the interaction 
model, the relative risk of CVE expressed as HR (95% CI) associated with the 
singular exposure of B/T ratio (B/T ratio >median;LDL ≤4.0), singular exposure 
of LDL (LDL >4.0;B/T ratio ≤median) and the combined exposure of B/T ratio 
and LDL (B/T ratio >median;LDL >4.0), is estimated compared to the reference 
group (B/T ratio ≤median;LDL ≤4.0). When RERI and AP are equal to 0 and SI 
simultaneously is equal to 1 there is no interaction (211). 
The area under the receiver-operating characteristics curve (AUC) was calculated 
in subjects with low compared to high LDL (≤ 4.0 and >4.0) to estimate the incre-
mental discriminatory value of the B/T ratio i.e. if the B/T ratio improved dis-
crimination of cases from non-cases. The B/T ratio was added to validate  markers 
of CVE risk including the FRS and IL6, both included as continuous variables.
3.3.3 Study III
In the primary analysis, differences between symptomatic and asymptomatic 
patients with regard to IL6, sIL6R and sgp130 plasma concentrations and IL6, 
IL6R, sIL6R, GP130, sGP130 gene expression in carotid artery plaques were 
analysed by means of Kruskal-Wallis rank test. 
In addition, differences in plasma levels and gene expression depending on to time 
passed from symptom to surgery (symptomatic patients) was analysed with the 
time variable dichotomised at 30 days. 
In secondary analyses, the correlation between plasma levels of IL6, sIL6R and 
sgp130 and plaque gene expression levels of IL6, IL6R, sIL6R, GP130, sGP130 
was analysed using Spearman’s rank correlation coefficient, rho. 
Furthermore, differences in plasma and plaque gene expression levels of IL6 and 
the receptors in statin and non-statin treated patients were analysed. Two individu-
als were excluded from the latter analysis: monotherapy with Ezetimibe (n=1) i.e. 
neither statin treatment nor free of lipid lowering agent and missing information 
on lipid lowering therapy (n=1). 
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3.3.4 Study IV
Cox proportional hazards model was used to assess the risk of future ischemic 
stroke associated with IL6 trans-signalling, estimated by the B/T ratio dichotomised 
at the median, with risk expressed as HR with 95% CI. 
The risk of future ischemic stroke in participants with and without prevalent or 
incident AF was analysed in the primary analysis. Estimates were presented crude 
and adjusted for the same cardiovascular risk factors as in Study I and II (sex, 
BMI, hypertension, diabetes mellitus, hypercholesterolemia and smoking) and in 
addition long-term anticoagulant treatment reported at baseline. Anticoagulants 
were categorised based on the codes from the Anatomic Therapeutic Chemical 
classification system, ATC: B01AA (vitamin K antagonists e.g. warfarin) or 
B01AB (heparin group). 
The risk of incident AF associated with the B/T ratio was analysed in secondary 
analyses. To analyse the nature of the association between the B/T ratio and the 
outcome, incident AF, the B/T ratio was initially categorised in quartiles and then 
dichotomised at the median. In addition, the association between IL6, sIL6R and 
sgp130, components in the B/T ratio, and the risk of AF was investigated. 
In secondary analyses, regression analyses were adjusted for sex, hypertension, 
BMI, and left ventricular hypertrophy (LVH). LVH was defined based on standard 
12-lead resting ECG and using the validated criteria of the Minnesota Code and 
the Cornell voltage–duration product. Either one of the two diagnostic scores had 
to be positive for the ECG findings to be defined as LVH. To validate the LVH 
categorisation, 10% of ECG samples were randomly selected (n=400) and evalu-
ated by Professor Sverker Jern’s research group in Gothenburg, Sweden. There 
was 83% correspondence between the two ECG assessments (212). 
A sensitivity analysis was performed to analyse the nature of the association 
when excluding IL6 values >20 pg/mL (n=18) potentially mirroring other types 
of inflammatory or infectious conditions. 
Given the effect of age on the risk of AF, cumulative incidence of AF was pre-
sented graphically in Kaplan Meier curves stratified by the B/T ratio dichotomised 
at the median. In addition, cumulative incidence graphs were presented stratified 
by quartiles of IL6, sIL6R and sgp130. As IL6 was the only one of the three IL6 
trans-signalling components that displayed a trend towards a higher AF incidence 
with increasing concentrations in particular above the 75th percentile, this marker 
was stratified by the 75th percentile presented in an additional graph. Given that 
survival curves cannot take into account potential confounders, quantile regression 
for censored data implemented using Laplace regression analysis, expressed in 
years with a 95% CI was applied to adjust for the above-mentioned confounders. 
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4 RESULTS 
4.1 Study I
Table 3 shows the most relevant clinical characteristics of the study participants 
from the 60YO cohort (n=3624) included in the Study I. Incident cases show a 
higher proportion of individuals exhibiting the traditional cardiovascular risk 
factors. In addition, levels of IL6, sIL6R and sgp130 were significantly higher in 
cases of CVE compared to the referents (p=0.0001 for IL6 and sIL6R and 0.005 
for sgp130).
Table 3. Clinical characteristics of the study population at baseline.
Cases (n=525) Referents (n=3099)
Female (%) 36.2 55.7
Systolic blood pressure, mm Hg 144.5 (132-159.5) 134.5 (121-150)
Diastolic blood pressure, mm Hg 87.5 (81.5-94.5) 82.5 (76-90)
BMI, kg/m2 27.0 (24.5-29.8) 26.1 (23.7-28.8)
Biochemical measurements (mmol/L)
LDL cholesterol 4.0 (3.4-4.6) 3.8 (3.2-4.5)
Fasting glucose 5.3 (4.9-5.9) 5.2 (4.8-5.6)
CV risk factors (%)
Hypertension 20.2 15.0
Hypercholesterolemia 4.2 3.4
Diabetes mellitus 6.3 2.3
Current smoking 29.2 19.8
IL6 system 
IL6 (pg/mL) 0.64 (0.46-0.95) 0.57 (0.41-0.86)
sIL6R (ng/mL) 36.7 (29.6-45.4) 32.8 (26.7-40.7)
sgp130 (ng/mL) 391.5 (334.3-459.4) 381.4 (317.5-448.9)
Continuous data are presented as median (IQR) and categorical data are presented as 
 percentages. Missing values (available in cases/referents): systolic and diastolic blood 
 pressure n=3 (525/3096), LDL n=45 (511/3068) and smoking n=44 (520/3060). 
Reproduced with permission from Ziegler et al, Interleukin 6 trans-signalling and risk of future 
cardiovascular events, Cardiovascular Research. 2019;115:213-221 (Study I).
We analysed of the association of each component in IL6 trans-signalling with 
the risk of CVE: IL6 and sIL6R showed a linear association (Figure 10, Panel A 
and B). 
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In the adjusted analysis, 0.1 pg/mL IL6 serum level increase was associated with 
CVE with an HR 1.00 and 95% CI 0.996–1.003, whereas 1 ng/mL sIL6R increase 
was associated with CVE with an HR 1.02 and 95% CI 1.01–1.02. 
On the other hand, sgp130 exhibited a non-linear association with the CVE risk, as 
seen in Figure 10, Panel C. CVE risk increased progressively with increasing sgp130 
concentrations up to the 75th percentile and slowly decreased at higher serum levels. 
In particular, levels above the 90th, and even more so above the 95th, percentile were 
associated with a CVE risk reduction.
Figure 10. Graphical representation of the association of serum IL6  concentrations 
(Panel A), sIL6R (Panel B) and sgp130 (Panel C) with time to first-time CVE 
 modelled using natural cubic splines.
Panel A. 
Panel B.
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Panel C.
Figure 10. Graphical presentation of the association between increasing serum concen-
trations of IL6 (pg/mL) (Panel A), sIL6R (ng/mL) (Panel B), and sgp130 (ng/mL) (Panel 
C) with the risk of CVE estimated by Cox regression using natural cubic splines and 
expressed as hazard ratio. 
Reproduced with permission from Ziegler et al, Interleukin 6 trans-signalling and risk 
of future cardiovascular events, Cardiovascular Research. 2019;115:213-221 (Study I).
While these analyses were relevant to understand the relationship of each bio-
marker with the CVE risk, they did not give us any information on the association 
of the IL6 trans-signalling and CVE risk. To analyse whether IL6 trans-signalling 
associates with the CVE risk, we estimated the circulating levels of the binary 
(IL6:sIL6R) and ternary (IL6:sIL6R:sgp130) complexes taking into account the 
molar concentration. The three biomarkers interact in fact on a molar basis and this 
transformation is necessary to estimate their relative amounts. From the binary and 
ternary complex, we calculated the ratio between the two, the B/T ratio, under the 
assumption that an excess of the binary complex or of the ternary complex could 
be associated with the outcome. 
Our analysis shows that B/T ratio had a monotone association with CVE risk 
(Figure 11). For every increase of 0.1 unit of the B/T ratio the CVE risk increased 
with a crude HR 1.45 and 95% CI 1.28–1.64 and an adjusted HR 1.31 and 95% 
CI 1.13–1.51 (p < 0.001 in both models). 
The results from the natural cubic splines analysis indicated that the median was 
an adequate cut-off with a risk decrease observed with B/T ratio levels <median 
(relative excess level of the ternary complex) and increased risk with levels >median 
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(relative excess level of the binary complex). With the median as cut-off, there 
was an increased CVE risk associated with the B/T ratio >median compared to the 
reference (≤median) with an adjusted HR 1.44 and 95% CI 1.21–1.72 (Table 4, 
lower section). 
Figure 11. The binary/ternary complex ratio association with CVE
Figure 11. Graphical presentation of the association between increasing serum values of 
the binary/ternary complex ratio with the risk of CVE estimated by Cox regression using 
natural cubic splines and expressed as hazard ratio.
Table 4. Risk of CVE associated with the B/T ratio
Binary/ternary 
complex ratio
N case/ref 
All: 525/3099
Crude 
(n=3624)
P Adjusted 
(n=3580)
P
< 20th 73/652 0.74 (0.55-1.01) 0.06 0.82 (0.60-1.11) 0.19
20-40th 86/639 0.88 (0.66-1.18) 0.41 0.89 (0.66-1.19) 0.43
40-60th 96/629 1 (ref) 1 (ref)
60-80th 130/595 1.39 (1.07-1.81) 0.02 1.30 (1.00-1.70) 0.05
80-100th 140/584 1.51 (1.17-1.96) 0.002 1.29 (0.99-1.67) 0.06
≤median 205/1607 1 (ref) 1 (ref)
>median 320/1492 1.63 (1.37–1.95) <0.001 1.44 (1.21–1.72) <0.001
Adjusted model adjusted for sex, BMI, hypertension, diabetes, hypercholesterolemia and 
smoking. The adjusted model contains fewer subjects (cases=520) due to missing values as 
described in Table 1. Reference group for the binary/ternary complex ratio: 40-60th percentiles 
in first analysis and ≤median in the second. Ref=references i.e. subjects without a CVE.
Reproduced with permission from Ziegler et al, Interleukin 6 trans-signalling and risk of future 
cardiovascular events, Cardiovascular Research. 2019;115:213-221 (Study I).
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We analysed this association further, looking into categories of the B/T ratio 
(<20th; 20-40th; 40–60th; 60-80th and >80th percentiles) with the category containing 
the median (40-60th percentiles) as the reference group. There was an indication 
of a decreased CVE risk associated with the B/T ratio <40th percentile (represent-
ing a relative excess of the ternary complex) although this association was not 
significant. B/T ratio levels >60th percentile (representing an excess of the binary 
complex) were on the other hand associated with a 30% risk increase with a close 
to doubled number of cases compared to the two low B/T ratio groups (Table 4, 
top section). 
In addition, adjusting for medical treatment, drugs affecting inflammation did not 
change the risk estimates (data not shown). 
The same pattern of association between the B/T ratio CVE risk was seen assum-
ing ten times higher and lower dissociation constants (Figure 12). 
Figure 12. Graphical presentation of risk associated with the binary/ternary 
complex ratio with different dissociation constants.
Figure 12. Risk of CVE associated with increasing levels of the binary/ternary complex 
ratio estimated by Cox regression assuming different dissociation constants for the binary 
(KD1) and ternary complex (KD2). The dissociation constants are expressed in nM.
Reproduced with permission from Ziegler et al, Interleukin 6 trans-signalling and risk 
of future cardiovascular events, Cardiovascular Research. 2019;115:213-221 (Study I).
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A modest increment in the discriminatory value measured with the AUC was the 
result of adding the B/T ratio to the FRS and IL6: FRS + IL6 + B/T ratio 0.62 
(0.59–0.64) vs. FRS + IL6 0.59 (0.56–0.62). In the reclassification analysis, add-
ing the B/T ratio to FRS + IL6 reclassified 10% of the patients correctly (NRI= 
+ 0.10, P=0.006 for FRS + IL6 + B/T ratio vs. FRS + IL6).
4.2 Study II
The study population’s clinical characteristics are described in Table 3 (Study I). 
The analyses in this study follow our observations in Study I. Given the relevance 
of LDL-cholesterol in determining CVE risk, we sought to investigate if a B/T 
ratio >median could be a predictor of risk in the presence of LDL ≤4.0, the most 
suitable cut-off to predict LDL associated increased CVE risk in our population 
based the ROC curve and sensitivity and specificity analyses. In primary analyses 
we estimated the risk of CVE associated with a B/T ratio >median in study par-
ticipants with LDL ≤4.0 compared with the CVE risk in those with higher LDL. 
We observed that the highest CVE risk was observed in participants with low LDL 
(HR 1.59 vs 1.29) in the presence of B/T> median, as seen in Table 5. 
Table 5. Risk of CVE associated with the B/T ratio > median and stratified by 
LDL levels.
Type of event Crude Adjusted
HR  
(95% CI)
p N  
(case /ref)
HR  
(95% CI)
p N  
(case/ ref)
Composite 
CVE (n=525)
LDL ≤4.0 1.79  
(1.39-2.29)
<0.001 259/1871 1.59  
(1.24-2.05)
<0.001 257/1850
LDL >4.0 1.45  
(1.13-1.87)
0.004 252/1197 1.29  
(1.00-1.67)
0.049 249/1179
The risk of composite CVE associated with the B/T ratio > vs. ≤median estimated by Cox 
regression expressed as HR (95% CI). In the adjusted analysis estimates were adjusted for 
sex, BMI, hypertension, diabetes mellitus and smoking. Reproduced with permission from 
Ziegler et al, The predictive role of interleukin 6 trans-signalling in middle-aged men and 
women at low-intermediate risk of cardiovascular events, European Journal of Preventive 
Cardiology. 2020;27:122-129 (Study II).
In addition, the difference in time to CVE associated with a B/T ratio >median vs. 
≤median was analysed according to LDL levels. B/T ratio >median was associated 
with earlier onset of CVE in individuals with LDL ≤4.0 (Figure 13, left panel) 
as compared to those with B/T ratio≤median. At the time-point when 10% of the 
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study population with LDL ≤4.0 had experienced a CVE, after around16 years of 
follow-up, subjects with a B/T ratio >median had their CVE four years earlier. In 
the group with LDL>4.0, presence of B/T ratio> median did not associate with 
earlier debut of CVE (Figure 13, right panel).
Figure 13. Differences in time to CVE with the B/T ratio stratified by LDL
Proportion
CVE
Time in years (95% CI) to CVE with B/T ratio > median and low/high LDL levels
LDL ≤ 4.0 LDL > 4.0
Crude P Adjusted P Crude P Adjusted p
5% -3.3 (-0.5; -6.0) 0.02 -1.4 (1.6; -4.4) 0.35 -1.7 (0.3; -3.7) 0.09 -0.3 (2.4; -3.1) 0.82
10% -5.5 (-3.6; -7.5) <0.001 -3.9 (-2.0; -5.8) <0.001 -2.7 (-0.6; -4.8) 0.01 -2.5 (0.3; -5.3) 0.08
15% NA - NA - -4.1 (-1.2; -6.9) 0.005 -1.5 (0.6; -3.6) 0.17
Figure 13. Difference	in	years	(95%	CI)	to	CVE	with	B/T	ratio	>	median	vs.	≤	median	in	
subjects	with	LDL	≤4.0	and	>4.0	mmol/L.	Case/referent	numbers	in	the	crude	analysis:	
LDL	≤4.0	group:	259/1871 (14% cases), and LDL >4.0 group: 252/1197 (21% cases). 
Missing data on LDL n= 45. NA= not applicable. Reproduced with permission from 
Ziegler et al, The predictive role of interleukin 6 trans-signalling in middle-aged men and 
women at low-intermediate risk of cardiovascular events, European Journal of Preventive 
Cardiology. 2020;27:122-129 (Study II).
To further analyse the association between the B/T ratio and CVE in individuals 
with low-intermediate cardiovascular risk we went on to investigate the effect B/T 
ratio stratified by LDL with an additional cut-off at a lower level creating three 
groups; LDL<3.0 (n=532), LDL 3.0–4.0 (n=1598) and LDL >4.0 (n=1494). As 
the optimal discriminatory value in our cohort was LDL 4.0, the lower cut-off has 
a lower discriminatory value in addition to the sub-group being small with few 
cases (n=61). We did however see an increased relative risk of CVE associated 
with a B/T ratio >median in the two sub-groups below 4.0 mmol/L, albeit not 
statistically significant in the small <3.0 mmol/L group (Table 6). 
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Table 6. CVE risk associated with B/T ratio> median stratified by LDL  
<3.0, ≥3.0-≤4.0, >4.0 mmol/L.
LDL (mmol/L) N ref/case Crude HR (95% CI) P Adjusted HR (95% CI) P
< 3.0 471/61 1.74 (1.05-2.91) 0.03 1.45 (0.86-2.47) 0.16
≥3.0-≤4.0 1400/198 1.80 (1.35-2.40) <0.001 1.64 (1.22-2.19) 0.001
> 4.0 1197/252 1.45 (1.13-1.87) 0.004 1.29 (1.00-1.67) 0.049
Ref/case: referents/incident cases. Risk of CVE expressed as hazard ratio (HR) with 95% 
confidence interval (CI). Multivariate analysis adjusted for sex, BMI, hypertension, diabetes 
and smoking. Reproduced with permission from Ziegler et al, The predictive role of interleukin 
6 trans-signalling in middle-aged men and women at low-intermediate risk of cardiovascular 
events, European Journal of Preventive Cardiology. 2020;27:122-129 (Study II).
In addition, we analysed the risk of CVE associated with a high B/T ratio in sub-
jects with low, intermediate and high 10-year risk of CVE according to the FRS 
and found that the B/T ratio was associated with an increased CVE risk only in 
participants classified as at low or intermediate risk by the FRS (Table 7).
Table 7. CVE risk associated with B/T ratio in individuals with low, intermediate 
and high CVE risk defined by the Framingham risk score.
10-year CVE risk N ref/case HR (95% CI) P
≤ 10% 2287/274 1.27 (1.00-1.61) 0.047
> 10%-≤ 20% 632/158 1.78 (1.36-2.34) <0.001
> 20% 138/88 1.48 (0.95-2.32) 0.087
Ref/case: referents/incident cases. Risk of CVE expressed as HR (95% CI). Missing values 
for the FRS=47. Given that the cardiovascular confounders incorporated in the multivariate 
analyses are all included in the FRS, estimates presented in the table are crude. Reproduced 
with permission from Ziegler et al, The predictive role of interleukin 6 trans-signalling in middle-
aged men and women at low-intermediate risk of cardiovascular events, European Journal of 
Preventive Cardiology. 2020;27:122-129 (Study II).
In secondary analyses, we analysed the B/T ratio associated with relative risk of 
coronary events (n=361) and ischaemic stroke (n=164) separately and in addi-
tion the difference in time to the respective event in relation to the B/T ratio. All 
analyses were stratified by LDL. The B/T ratio was solely associated with an 
increased risk of having future CAD (HR 1.52; 95% CI 1.11–2.08) and ischaemic 
stroke (HR 1.84; 95% CI 1.19–2.83) amongst subjects with LDL ≤4.0 while no 
association was seen for either type of event in those with higher LDL (Table 8). 
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Table 8. Risk of coronary events and ischemic stroke associated with the B/T 
ratio >median stratified by LDL levels.
Type of event Crude Adjusted
HR  
(95% CI)
p N  
(case /ref)
HR  
(95% CI)
p N  
(case/ ref)
Coronary events 
(n=361)
LDL ≤4.0 1.79  
(1.32-2.44)
<0.001 170/1871 1.52  
(1.11-2.08)
0.009 168/1850
LDL >4.0 1.44  
(1.07-1.94)
0.015 184/1197 1.28  
(0.95-1.73)
0.10 182/1179
Ischemic Stroke 
(n=164)
LDL ≤4.0 1.86 
(1.21-2.85)
0.004 89/1871 1.84 
(1.19-2.83)
0.006 89/1850
LDL >4.0 1.58 
(0.97-2.57)
0.07 68/1197 1.41 
(0.86-2.31)
0.18 67/1179
The risk of coronary events and ischemic stroke associated with the B/T ratio > vs. ≤median 
estimated by Cox regression expressed as HR (95% CI). In the adjusted analysis estimates 
were adjusted for sex, BMI, hypertension, diabetes mellitus and smoking. 
Reproduced with permission from Ziegler et al, The predictive role of interleukin 6 trans-
signalling in middle-aged men and women at low-intermediate risk of cardiovascular events, 
European Journal of Preventive Cardiology. 2020;27:122-129 (Study II).
In the time to event analysis, CAD events occurred significantly earlier (3–4 years) 
with a B/T ratio >median irrespective of the LDL level albeit the association was 
stronger in the group with lower LDL (p<0.001 compared to p=0.03). Individuals 
with ischaemic stroke on the other hand experienced earlier events solely in the 
LDL ≤4.0 group (3.8 years, p=0.02) as seen in Figure 14.
We then tested the effect of the interaction between LDL-cholesterol levels and 
B/T ratio on the risk of CVE. These two factors are biologically related in the 
progression of atherosclerosis, however our data seemed to indicate a specific 
pattern of association were the B/T ratio was able to predict CVE risk in subjects 
with low-normal cholesterol levels. 
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The risk of CVE associated with exposure to IL6 trans-signalling alone or LDL 
alone or both in combination was compared to the reference group with no expo-
sure of either one. The regression analysis displayed a comparable risk increase 
when either of the two exposures; B/T ratio and LDL, was present (HR 1.58; 95% 
CI 1.23 -2.04 and HR 1.68; 95% CI 1.27 -2.21, respectively). The combination 
of the two exerted the highest CVE risk (HR 2.17; 95% CI 1.68–2.80) as shown 
in Figure 15. The risk associated with both LDL and the B/T ratio was however 
not higher than the sum of the risk associated with LDL or the B/T ratio alone. 
Together with RERI -0.04, AP -0.01 and SI 0.97 with p=0.9, this suggests that the 
two exposures do not interact. 
To test the incremental discriminatory value of the B/T ratio, the AUC for the 
continuous FRS and IL6 plus the addition of the B/T ratio was analysed. In the 
unstratified cohort the AUC including the B/T ratio was 0.67 while when  stratifying 
by low or high LDL (≤ or >4.0 mmol/L), the AUC was 0.68 in the LDL ≤4.0 group 
and 0.65 in the >4.0 group, indicating an increased incremental value adding the 
B/T ratio to existing risk markers in groups of low-normal LDL values.
Figure 14. Differences in time to ischemic stroke associated with the B/T ratio 
stratified by LDL-cholesterol levels ≤ 4.0 and >4.0 mmol/L.
Proportion Time to ischemic stroke with B/T ratio > median and LDL ≤ or > 4.0 mmol/L
stroke LDL ≤ 4.0 LDL > 4.0
Crude p Adjusted p Crude P Adjusted p
2.5% -3.3 (-0.7; -6.0) 0.01 -3.7 (2.1; -9.5) 0.21 -1.2 (0.7; -3.0) 0.21 -0.2 (43.1; -43.5) 0.99
5% -6.5 (-4.1; -8.9) < 0.001 -3.8 (-0.7; -6.8) 0.02 -4.3 (-1.5; -7.2) 0.003 -1.5 (2.1; -5.0) 0.42
Figure 14. Differences in time (years; 95% CI) to ischemic stroke with the B/T ratio in 
subjects	with	LDL	≤4.0	and	>4.0	mmol/L.	Case/referent	numbers	in	the	adjusted		analysis:	
89/2018	in	LDL	≤	4.0	and	67/1361	in	LDL	>4.0.	Reproduced	with	permission	from	Ziegler	
et al, The predictive role of interleukin 6 trans-signalling in middle-aged men and women at 
low-intermediate risk of cardiovascular events, European Journal of Preventive Cardiology. 
2020;27:122-129 (Study II).
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Figure 15. The risk of CVE associated with the B/T ratio and LDL
B/T ratio ≤ median (n=1772)
B/T ratio > median (n=1763)
0
0,5
1
1,5
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2,5
LDL ≤ 4.0 (n=2107)
LDL > 4.0 (n=1428)
1.00
1.58
1.68
2.17
Figure 15. The risk of CVE associated with the B/T ratio alone (B/T ratio >median; LDL 
≤4.0	mmol/L),	LDL	alone	(LDL	>4.0	mmol/L;	B/T	ratio	≤	median),	B/T	ratio	in	combination	
with LDL (B/T ratio >median; LDL >4.0 mmol/L) compared to the reference group (B/T ratio 
≤median;	LDL	≤4.0	mmol/L).	Risk	calculated	by	Cox	proportional	hazards	model	presented	
as hazard ratio. All p <0.001. Missing data: LDL n=45 and smoking n=44. 
Reproduced with permission from Ziegler et al, The predictive role of interleukin 6 trans-
signalling in middle-aged men and women at low-intermediate risk of cardiovascular events, 
European Journal of Preventive Cardiology. 2020;27:122-129 (Study II).
4.3 Study III
The clinical characteristics of the BiKE study population analysed in the present 
study is summarised in Table 9. Among asymptomatic patients there were more men, 
hypertensives and subjects with overweight while symptomatic participants were older. 
Table 9. Clinical characteristics of the study population stratified stroke 
 symptoms preceding CEA
All (n=78) Symptomatic (n=53) Asymptomatic (n=25)
Age (years) 73 (65-78) 76 (68-80) 68 (60-73)
Males (%) 74.4 64.1 96.0
Hypertension (%) 85.9 81.1 96.0
Diabetes mellitus (%) 29.5 28.3 32.0
Statin treated (%) 86.3 80.0 89.1
Overweight (%) 54.2 46.8 68.0
Smoking (%) 26.5 26.1 27.3
Missing information on statin treatment (n=2).
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The analysis of the expression of IL6, IL6R, sIL6R, GP130 and sGP130 shows that 
all the genes were expressed in carotid plaques. Moreover, both membrane-bound 
receptor genes (GP130 and IL6R) displayed a higher expression level than their 
respective soluble form (sGP130 and sIL6R) as seen in Figure 16. 
Figure 16. IL6 signalling gene expression levels in carotid artery plaques
Figure 16. Relative gene expression levels of GP130, sGP130, IL6R and sIL6R in carotid 
plaques	(n=78)	measured	by	semi-qRT-PCR	and	reported	as	-	ΔCT. P-value for relative 
differences in expression.
Comparing gene expression levels in symptomatic and asymptomatic patients, 
IL6R displayed a higher expression level in symptomatic patients as compared 
to asymptomatic (p=0.007). The same trend was seen for sIL6R, notwithstanding 
without statistical significance (p=0.06). Contrarily, GP130 and sGP130 exhibited 
higher expression levels in asymptomatic patients as compared to symptomatic 
without attaining statistical significance (p=0.05 and p=0.08, respectively) (Figure 
17). On the other hand, IL6 expression levels did not differ between symptomatic 
and asymptomatic patients (IL6 log2 median: 6.46 vs 6.18, p=0.37). 
To assess whether potential differences could be attributed to the time span from 
symptom to surgery, time from symptom to CEA was incorporated as a factor in the 
analysis. Gene expression and plasma levels were stratified by time from symptom 
to surgery in symptomatic patients resulting only in higher sIL6R plasma levels in 
those with symptoms ≤30 days before CEA as compared to those with symptoms 
>30 days (median 73.3 vs 55.8 ng/mL, p=0.02) before CEA. No difference was 
observed for IL6, sIL6R, sgp130 or hsCRP plasma levels. 
In secondary analyses, we explored the correlation between plasma levels of each 
biomarker and plaque gene expression levels. Our results show a moderate and 
borderline significant positive correlation between plasma IL6 and sIL6R with 
of IL6 and sIL6R (both p=0.05), respectively. Furthermore, an indication, albeit 
statistically insignificant, of positive correlations was observed for sIL6R with 
GP130 and sGP130 (Figure 18). No differences in correlations could be detected 
comparing symptomatic and asymptomatic subjects (data not shown). 
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Figure 18. Correlations between plasma levels and plaque expression
Figure 18. Scatter plots representing correlations between plasma IL6 and sIL6R levels 
and gene expression of IL6 and sIL6R in carotid plaques. Correlations were estimated 
using Spearman’s rank correlation coefficient, rho.
Figure 17. IL6 signalling gene expression levels in symptomatic and 
 asymptomatic plaques
Figure 17. Relative gene expression levels of GP130, sGP130, IL6R and sIL6R in carotid 
plaques in asymptomatic and symptomatic study participants, quantified by semi-qRT-PCR 
and	expressed	as	-	ΔCT. P-value for differences between asymptomatic and symptomatic 
patients.
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Plasma levels of IL6, sIL6R, sgp130 and hsCRP did not correlate with each other 
except for IL6 and hsCRP (rho 0.45, p=0.0004). 
Given the interplay between cholesterol and inflammation in atherosclerosis, 
additional analyses were performed to address differences in statin-treated vs. 
non-treated patients. In the subset of the cohort analysed in this thesis, ≥80% of 
patients were treated with statins. The largest difference between statin-treated and 
non-treated patients was seen for sIL6R with higher plasma levels in statin-treated 
patients (sIL6R median 66.96 vs. 60.9 ng/mL, p=0.05). Regarding gene expres-
sion, IL6 expression did not differ while IL6R, sIL6R and sGP130 were relatively 
more extensively expressed in plaques from patients on statin treatment compared 
to non-treated (Figure 19).
Figure 19. IL6 signalling gene expression levels in statin treated and 
non-treated
Figure 19. Relative gene expression of GP130, sGP130, IL6R and sIL6R in carotid plaques 
stratified by statin treatment (statin treated n=65, no statin n=11) quantified by semi-qRT-
PCR	and	expressed	as	-ΔCT. P-value for in expression between the groups.
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4.4 Study IV
The study population is the 60YO. Clinical characteristics differ slightly from those 
reported in Study I since the follow-up until December 31st 2017 were  available 
when these analyses were performed. In addition, in this study we focused on 
ischemic stroke following our observations in Study II, where we observed a 
stronger association of the B/T ratio with the risk of ischemic stroke and Study III 
where we had observed that all the component of the IL6 trans-signalling were 
expressed in the carotid plaques. Therefore, study participants with prevalent and 
incident CAD have been excluded from the analysis. The clinical characteristics 
of the study population included in this study are presented in Table 10.
After 20-year follow-up, 203 fatal and non-fatal ischemic strokes had occurred. 
At baseline 29 subjects had prevalent AF whereas 279 individuals got a first-ever 
diagnosis of AF during follow-up. Participants with prevalent or incident AF suf-
fered more often ischemic strokes than participants without AF. B/T ratio did not 
differ between the two groups. 
Table 10. Baseline characteristics of the study population stratified by case 
and non-case status
Baseline characteristics Ischemic stroke  
(n=203)
No ischemic stroke  
(n=2990)
Male (%) 116 (57.1) 1309 (43.8) 
Hypertension (%) 45 (22.2) 440 (14.7) 
Hyperlipidaemia (%) 6 (3.0) 103 (3.4)
Diabetes mellitus (%) 10 (4.9) 76 (2.5) 
Atrial fibrillation (%) 5 (2.5) 23 (0.8)
Smoking (%) 56 (27.9) 589 (20.0)
Anticoagulant treatment (%) 1 (0.5) 11 (0.4)
BMI 26.5 (24.4-28.6) 26.0 (23.7-28.8)
Systolic blood pressure 143.5 (130.5-156.5) 134.5 (120.5-150)
Diastolic blood pressure 88 (81-94.5) 82.5 (76-90)
Glucose 5.2 (4.8-5.7) 5.2 (4.8-5.6)
LDL 4.1 (3.4-4.7) 3.8 (3.2-4.5)
b/t ratio 1.60 (1.56-1.63) 1.58 (1.55-1.61)
Continuous variables presented as median (IQR). BMI was expressed as kg/m2, blood 
 pressure as mm Hg, glucose and LDL as mmol/L. Missing data on: smoking (n=40), LDL 
(n=37) and blood pressure (n=3).
First we analysed the association of the B/T ratio >median (1.58) with the risk of 
future ischemic stroke in study participants with and without prevalent or incident 
AF and observed that in the presence of AF a significant association could not be 
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demonstrated (adjusted HR 1.54; 95% CI 0.81-2.91), while in subjects without an 
AF diagnosis a significant association was observed between B/T ratio and risk 
of ischemic stroke (adjusted HR 1.49; 95% CI 1.08-2.06).
We then analysed the association of the B/T ratio, categorised in quartiles or 
dichotomised at the median, with the risk of incident AF. The B/T ratio was not 
associated with the risk of AF in any of these analyses and consistently, no differ-
ence in AF prevalence proportion could be seen stratifying by the B/T ratio ≤ and 
> median throughout the follow up time (Figure 20, left panel).
Figure 20. Differences in time to AF diagnosis associated with the B/T ratio
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Figure 20. Kaplan Meier curve of the cumulative atrial fibrillation (AF) incidence in study 
participants without prevalent AF at baseline and stratified by the B/T ratio (left panel) 
and IL6 dichotomised at the 75th percentile (right panel).
As for CVE, we looked into the association of the single components of the IL6 
trans-signalling with the risk of AF. Exploring the association between IL6 and AF, 
the risk estimates suggested increased risk associated IL6 levels >75th percentile 
albeit without statistical significance (HR1.23; CI 0.93-1.63). When excluding IL6 
>20 pg/mL in a sensitivity analysis, a modest risk estimate change was observed 
(HR1.27; CI 0.96-1.67). 
However, we observed that individuals with IL6 levels >75th percentile were diag-
nosed with AF earlier (Figure 20, right panel) than those with lower IL6 levels. 
At the end of follow-up, the proportions of participants with AF were 6 and 10% 
for the IL6 ≤ and > 75th percentile, respectively. Applying Laplace regression to 
quantify the difference in time between the two groups and adjust for confound-
ers, resulted in a 3-year difference (95% CI 0.3-5.7 years, p=0.03) with earlier AF 
diagnosis in those with the highest IL6 levels at the end of follow-up. The soluble 
IL6 trans-signalling receptors, sIL6R or sgp130 were not associated with the risk 
of AF or with an earlier AF diagnosis. 
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5 DISCUSSION
The main finding of the studies within this thesis is that the IL6 trans-signalling, 
estimated by the binary/ternary complex ratio (B/T ratio), is associated with 
 atherosclerosis driven coronary and cerebrovascular events. 
In Studies I and II, we demonstrate an association between the B/T ratio and an 
increased risk of future CVE in middle-aged individuals without prevalent CVD, in 
particular in those with low-intermediate cardiovascular risk based on LDL levels 
or the FRS. Results from Study II also indicate a stronger association of the B/T 
ratio with the risk of ischemic stroke.
In Study III, we sought to investigate whether IL6 trans-signalling is present in 
manifest atherosclerosis. Although far from inferring causality of the association 
between IL6 trans-signalling and atherosclerosis related CVE, our results provide 
evidence for the existence of a local IL6 signalling. All IL6 signalling components 
are expressed in the carotid plaques and in addition they seem to be differentially 
expressed depending of the instability of the plaque. This may imply the presence 
of an autocrine/paracrine IL6 trans-signalling that could interact and cooperate 
with the systemic IL6 trans-signalling in the progression of atherosclerotic plaques.
In Study IV, we have tried to disentangle the role of IL6 trans-signalling as  predictor of 
two common forms of ischemic stroke, the atherothrombotic and  cardioembolic. We 
found that the B/T ratio was associated with the risk of future ischemic stroke only in 
individuals without AF while no association could be established for ischemic stroke 
in subjects with AF. Moreover, the B/T ratio was not associated with AF incidence per 
se. Altogether, our results indicate that IL6 trans-signalling is a relevant and specific 
predictor of the risk for atherosclerosis related CVE. In addition, we propose a novel 
biomarker that integrates the components of the IL6 trans-signalling in one entity, the 
B/T ratio, with high levels representing a relative excess of the active binary IL6:sIL6R 
complex in relation to the inactivated ternary IL6:sIL6R:sgp130. 
Clinical science and practice have come a long way on the cholesterol path in 
 atherosclerosis preventive treatment but has only just entered that of inflammation. 
The results of the CANTOS trial indicate a possible beneficial effect of IL1β-IL6-
CRP pathway inhibition in patients with stable CAD on optimal  secondary preven-
tive treatment (12). In sub-analyses of the CANTOS study, it was demonstrated 
that participants with the highest pre-treatment IL6 concentrations and in addition 
significant on-treatment decrease in IL6 or hsCRP levels had the greatest effect 
indicating a central role for IL6 (213, 214).
Similar results were observed in the COLCOT trial where treatment with the anti-
inflammatory IL1β inhibiting Colchicine exerts a protective effect on recurrent CVE 
after recent MI, comparable to that observed with canakinumab (215). When stratify-
ing by event type, the risk reduction was primarily driven by decreased stroke risk. 
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In spite of the exciting findings from ILlβ inhibition studies, there are nega-
tive aspects of inhibiting the entire IL1β-IL6-CRP pathway. The Federal Drug 
Administration (FDA) has not approved the use of canakinumab in clinical practice 
because of a high cost/benefit ratio as well as for the increased risk of severe and 
fatal infections due to the impairment of the immune response (12, 215). 
Our studies cannot answer the question on the suitability of IL6 trans-signalling as 
target for treatment of atherosclerosis related CVE, intervention studies are needed 
to firmly answer this question. However, given the strong biological evidence 
linking the IL6 trans-signalling to the inflammatory response in atherosclerosis 
and the observed associations with the risk of CAD and ischemic stroke reported 
in our studies, we believe that moving downward in the IL1β-IL6-CRP pathway 
and targeting the pro-inflammatory IL6 trans-signalling is attractive and worth 
exploring (Figure 21). Targeting IL6 trans-signalling could represent an innova-
tive treatment moiety to modulate inflammation in atherosclerosis avoiding the 
inhibition of the pivotal IL6 classical signalling and the associated negative effect 
on the immune response.
Figure 21. Schematic presentation of levels of inhibition of the IL1β-IL6-CRP 
pathway
Pro-IL1β
NPLR3 inhibitorsColchicine
Monoclonal IL1β anbody –
Canakinumab
Monoclonal IL6 anbody –
Tocilizumab
Recombinant antagonist of
trans-signalling sgp130Fc
Figure 21. Adapted with permission from Ziegler et al, Interleukin 6 trans-signalling and 
risk of future cardiovascular events, Cardiovascular Research. 2019;115:213-221 (Study I).
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5.1 Study I 
The main novelty of Study I is the use of the B/T ratio as measure of active IL6 
trans-signalling and as a risk predictor for future CVE.
As compared to previous studies, we have for the first time incorporated the active 
and inactive moieties of this signalling system in one biomarker. 
There are some important limitations to this approach. The B/T ratio was calcu-
lated from the estimated molar concentration of the binary IL6:sIL6R complex 
and the ternary IL6:sIL6R:sgp130 complex. The calculation derives from the 
formulas originally published in a paper by Müller-Newen et al. based on results 
from in vitro studies (75, 101). The rationale underlying this approach is that the 
interaction among IL6, sIL6R and sgp130 occurs on a molar basis and not on the 
basis of their mass. However, we cannot exclude that in physiological conditions, 
the dissociation constants are different from the ones we have used. To verify that 
the association of the B/T ratio with the outcome holds even with higher or lower 
dissociation constants, we performed the association analysis assuming that the 
dissociation constants were 10 times higher and 10 times lower and found that the 
association withheld. Since this is a prospective analysis, a potential error would 
have resulted in a non-differential misclassification thus not affecting the risk 
estimates. In addition, the B/T ratio cut-off was data driven which potentially can 
prevent generalisability of the results to other populations. Our ambition is how-
ever not to disclose reference values and cut-offs for future analyses but rather to 
explore the association between active IL6 trans-signalling and CVD. 
Another major limitation is the possibility to use this biomarker in the daily prac-
tice. The computational step and the need to measure three biomarkers make this 
approach not easy to implement and potentially expensive. As with other novel 
biomarkers it is however possible that measurement of the B/T ratio might be 
advocated to guide treatment in selected groups of individuals and patients, as for 
example patients with chronic autoimmune disorders or as suggested in Study II 
in those with low-normal LDL cholesterol levels. 
On the other hand, the importance of creating an “integrated” biomarker is sug-
gested by the data reported in Study I. We observed, in line with previous studies, 
that IL6 and sIL6R displayed a linear association (26, 148-151, 216). Hence, both 
IL6 and sIL6R are markers of increased risk, albeit only the two in combination 
or sIL6R alone mirrors IL6 trans-signalling exclusively. IL6 signalling is causally 
related to CAD via the genetically determined shedding of sIL6R (142, 217). In 
context of what we know of IL6 biology and together with the existent genetic 
and clinical data, the results from Study I suggest that the binary IL6:sIL6R 
complex is the active component rather than IL6 itself. Hence both entities are 
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needed to assess the activity in the pathway (83, 142, 148, 150-152). The picture 
is however not complete until sgp130 is added. In our study, sgp130 displayed 
a non-linear association and in previous observational studies, sgp130 has been 
associated with both protective and detrimental properties (114, 151, 153, 154). 
While administering supra-physiological doses of recombinant sgp130Fc resulted 
in dampened atherosclerosis and fewer ruptures of abdominal aortic aneurysms in 
two murine models of atherosclerosis (138, 140). Considering the above, physi-
ological sgp130 levels possibly mirrors the activity in the pathway rather than 
the level of IL6 trans-signalling inhibition. As the ability of sgp130 to inhibit IL6 
trans-signalling is completely dependent on the presence of the binary IL6:sIL6R 
complex, the protective effect of physiological sgp130 cannot be evaluated on 
its own. Moreover, we cannot exclude that sgp130 levels mirror other inflam-
matory processes independent from the IL6 trans-signalling. For instance, IL11 
trans-signalling is inhibited by sgp130Fc and in theory might also be inhibited by 
circulating sgp130 (218). 
Overall, we observed a strong and consistent association between the B/T ratio 
and the risk of CVE in line with previous studies on the association of the sIL6R 
with CVE risk (148-152). We then tested it the B/T ratio could improve the predic-
tion of CVE. The measures of discrimination and re-classification were slightly 
increased which is in line with prior studies since these are models constructed 
for evaluating diagnostic and not predictive tools (219). In the models, we used 
the FRS as the reference and not the European SCORE which has cardiovascular 
mortality as outcome (8). In addition, IL6 was used instead of CRP as we wanted 
to analyse the potential improvement in prediction with the B/T ratio in relation 
to an existent risk markers albeit did not want to use CRP as it is not part of the 
trans-signalling pathway (220).
5.2 Study II
In Study II, we found that the risk of CVE associated with the B/T ratio >median 
was higher in subjects with LDL ≤4.0 mmol/L compared to those with higher 
LDL levels and in those with low-intermediate risk according to the FRS. This 
is the group of people where novel biomarkers are mostly advocated and those 
who potentially would benefit the most from the B/T ratio as a predictor of future 
CVE. Above all, in the intermediate cardiovascular risk group the assessment of 
potential re-classification upwards or downwards is of great importance to address 
the possible need for intervention (221). 
In addition, individuals with a B/T ratio >median experienced a higher CVE/CAD/
ischemic stroke risk and earlier events than those with lower B/T ratio and this 
was primarily evident among those with low LDL levels. 
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In spite of new guidelines, such as the European Guidelines on cardiovascular 
disease prevention in clinical practice from 2016, emphasising the need to risk 
stratify individually, patients are still treated in a secondary preventive manner 
resulting in insufficient preventive treatment for individuals without a first-ever 
CVE but a high cardiovascular risk (222).
To assess the risk associated with the B/T ratio, in individuals at low-intermediate 
and high cardiovascular risk, we chose to stratify by LDL with a cut-off of 
4.0 mmol/L. The 4.0 mmol/L cut-off gave us the best sensitivity and specificity 
for LDL as a predictive marker of CVE in our cohort. Harmonising with other 
studies, the cut-off was in line with levels re-classifying between risk groups in 
the FRS and in a Swedish cohort study (208, 223). The association was also tested 
stratified by the FRS <10%, 10-20% and >20% 10-year CVE risk and found to be 
a predictive marker in those at low-intermediate risk. These findings are in line 
with studies of other cardiovascular biomarkers displaying a greater discrimina-
tory potential in subjects at low risk (221, 224).
The more recent guidelines introduce a cut-off of 3.0 mmol/L for LDL cholesterol 
as target for eventual treatment with cholesterol lowering agents (225). Our data 
suggest that even with LDL levels lower than 4.0, the B/T ratio still predicts CVE. 
However, due to the small number of cases in the group with LDL <3.0 we could 
only demonstrate a trend similar to that of the analysis with the higher cut-off.
In the biology of atherosclerosis, the growth of the atherosclerotic plaque is depend-
ent on the interaction between oxidised-LDL, foam cells producing inflammatory 
mediators and anti-inflammatory cytokines. In our study we tested the presence of 
a biological interaction between LDL and the B/T ratio. We have used a biological 
interaction model on an additive scale: this model can be used if there is a strong 
biological hypothesis underlying a possible interaction between the two exposures. 
We observed that the effect of IL6 trans-signalling on the CVE risk was independ-
ent from that of LDL cholesterol when analysing the interaction between the two. 
The measure of interaction in fact did not show a significant increase in CVE risk 
in those with both high LDL levels and B/T ratio. An important consideration is 
that the absence of a statistically significant interaction may be due to lack of 
power. Therefore, these results can only be considered as hypothesis generating. 
One implication of this result, if confirmed in other populations, is that targeting 
the IL6 trans-signalling may have an effect which is independent from the one 
obtained targeting LDL with lipid lowering agents. To this extent, targeting the 
IL6 trans-signalling may achieve a different anti-inflammatory effect from that 
observed during statin treatment resulting in lower CRP levels. 
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5.3 Study III
In the first ever study analysing the local expression of IL6 signalling in human 
atherosclerotic plaques, we found that all components of IL6 signalling are pre-
sent in carotid plaques and that their expression seem to differentiate depending 
on the severity of the disease and statin treatment. Of importance, plasma sIL6R 
correlated with plaque expression of sIL6R. 
Plaques from patients who had suffered a cerebrovascular event ≤ 6 months prior 
to surgery displayed significantly higher expression of IL6R compared to asympto-
matic patients. Furthermore, expression analyses indicated higher sIL6R and lower 
GP130 and sGP130 expression in symptomatic patients. These findings confirm 
the local presence of IL6 signalling in carotid plaques and the pattern of differen-
tial expression suggests a possible association between local gene expression and 
plaque instability mirrored by the recent cerebrovascular event. In line with our 
findings, previous analyses of plaque gene expression in the BiKE study demon-
strated upregulation of inflammation associated genes in symptomatic subjects 
(205). Our findings are however suggestive as our cohort is small lack of statistical 
significance cannot be ruled out as absence of association. In a recent in vitro study 
on hepatocytes with a computational modelling approach, it was proposed that 
IL6 trans-signalling is the dominant IL6 pathway when gp130 protein expression 
exceeds IL6R expression (226). Given our transcriptomic approach and experi-
mental design we cannot draw any conclusions on which of the two IL6 pathways 
is more active. Nevertheless, the results of the gene expression analysis indicate 
a higher absolute expression level of GP130 compared to IL6R regardless of the 
symptomatic/asymptomatic status of the patient. In addition, upregulated GP130 
expression could be indicative of IL6 trans-signalling in line with the positive 
autocrine feedback loop described on vascular SMC (135). 
To assess if peripheral circulating levels of the IL6 signalling components mirror 
local activity in the IL6 pathways, we found that plaque expression of IL6 and 
plasma IL6 and plaque sIL6R and plasma sIL6R, respectively were positively cor-
related. Moreover, plasma sIL6R was the only marker that decreased with time 
from the cerebrovascular event to CEA indicating that the sIL6R could be used 
as a predictive biomarker of atherosclerosis and possibly also to monitor inflam-
matory activity locally in plaques. 
In additional analyses, the plaque expression and plasma levels were analysed with 
regards to whether or not the patient was on statin treatment. Here we found that 
sIL6R and sGP130 were expressed to a greater extent in plaques and plasma sIL6R 
was higher in statin-treated patients compared to non-treated. These findings of a 
potential upregulation of the IL6 trans-signalling components when subjected to 
statins are in line with our previous findings of the B/T ratio as a stronger predic-
tor in individuals with low-normal LDL cholesterol levels. 
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With these findings we conclude that IL6 signalling is present locally in carotid 
artery plaques. These results also suggest that circulating levels of the binary 
IL6:sIL6R complex could be used as a marker of prevalent atherosclerosis.
5.4 Study IV
Study IV concluded that the B/T ratio is associated with ischemic stroke in 
individuals without prevalent or incident AF while this association could not be 
 demonstrated in subjects with AF. In secondary analyses, we found that there was 
no association between the B/T ratio and risk of incident AF in individuals free 
of prevalent or incident CVD.
Ischemic stroke is a well-defined clinical condition resting on heterogeneous and 
complex pathophysiological ground making epidemiological studies on ischemic 
stroke challenging. In Study II, the B/T ratio >median was associated with the 
risk of ischemic stroke and earlier cerebrovascular events, albeit we had not strati-
fied by ischemic stroke type. To further analyse this association, we explored the 
presence of IL6 signalling in carotid plaques in Study III and found a pattern of 
suggestive differential gene expression depending on degree of plaque stability.
In Study IV, we were therefore curious to see if IL6 trans-signalling was primarily 
associated with atherothrombotic stroke or if there was also an association with 
AF and cardioembolic stroke. The inflammatory mechanisms in atherosclerosis 
of the carotid arteries are to a large extent similar to those in the coronary vessels 
while the environment in the intracerebral vasculature, not covered in this thesis, 
is much different owing to the cerebral blood pressure autoregulation, blood brain 
barrier and immune cells exclusive to the CNS (10). 
Given that sIL6R and sgp130 are produced through post-transcriptional mecha-
nisms, genetic studies demonstrating an association between IL6R, AF and ischemic 
stroke cannot differentiate between IL6 classical and IL6 trans-signalling but merely 
establish the association with IL6 signalling in general (194, 195). To explore the 
association between IL6 signalling and AF we analysed the association with each 
component of IL6 trans-signalling and found an association only with high levels 
of circulating IL6. Considering the increasing evidence of cardiac remodelling 
with atrial cardiopathy as a plausible mechanism for cardiac thromboembolism in 
AF, our results could potentially be explained by increased IL6 classical signalling 
known to be involved in vascular remodelling and in cardiac hypertrophy induced 
by angiotensin II (81, 180, 183, 227). 
Our results clearly suggest that IL6 trans-signalling is associated with atherothrom-
botic ischemic stroke while the association to AF and AF in relation to ischemic 
stroke could not be demonstrated. 
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In summary
Although the studies in this thesis prevent us from drawing any mechanistic conclu-
sions, our results are in line with what is known about the IL6 signalling biology 
and the results from existing clinical studies. With these findings we conclude that 
IL6 trans-signalling, estimated by the B/T ratio, is a potential predictive biomarker 
of future CVE, primarily in individuals with low-intermediate cardiovascular risk. 
Moreover, the presence of the signalling moieties in carotid artery plaques together 
with previous experimental mouse studies suggest that IL6 trans-signalling could 
be a novel target for immunomodulatory treatment of manifest atherosclerotic 
CVD and the B/T ratio could possibly be used to monitor treatment.
5.5 Methodological considerations
5.5.1 Study design
All studies in this thesis are observational and thus cannot contribute with mecha-
nistic evidence. 
Study I, II and IV were performed in the 60YO, a large prospective population-based 
cohort with a high positive response rate and complete follow-up of the outcome 
in national registers which diminishes the risk of selection bias. Conducting cohort 
studies with follow-up by means of national registers is effective, inexpensive 
and secures follow-up. In addition, prospective cohorts have the advantage that 
temporality can be assessed i.e. the exposure precedes the outcome. 
A limitation of the study design of the 60YO is the fact that blood sampling and 
gathering of information on e.g. medication only was performed at baseline thus 
preventing the assessment of variations in biomarker serum concentrations and 
changes in medication during follow-up. The single baseline measurement of the 
biomarkers could introduce a misclassification of the exposure. We have however 
only included participants without prevalent CVD at baseline. MI and ischemic 
stroke are preceded by several years of silent CVD albeit we have no knowledge 
of mechanisms inflicting a greater variation in cytokine and receptor levels in 
future cases of CVE than in referents. However, subjects with subclinical CVD 
could possibly have a greater variability in serum levels during follow-up due to 
low-grade chronic inflammation in the vessels. If so, the potential misclassifica-
tion would be differential and possibly affect the risk estimate.
In addition, at the time Study I and II were performed we did not have the ethical 
permission to retrieve diagnoses of other prevalent or incident non-cardiovascular 
outcomes from national registers in the 60YO. This has prevented us from ana-
lysing the risk associated with the B/T ratio in other disease where inflammation 
plays an important role as well as the competing risk with CVD.
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In Study III, we have analysed a sample from the BiKE study where we could 
assess all the components of the IL6 trans-signalling in both plasma and tissues. 
The sample size was however small possibly explaining the lack of statistical 
power to analyse the differentially in gene expression and correlations between 
gene expression and plasma levels. Moreover, the analyses were cross-sectional 
preventing temporality from being addressed. The major strength of Study III was 
that it was performed in a real-world setting of consecutive patients amenable 
for CEA in Stockholm 2002-2007 thus increasing potential generalisability and 
minimising selection bias.
5.5.2 Misclassification of the exposure 
5.5.2.1 Biomarker measurements
Circulating levels of IL6, sIL6R and sgp130 were measured in serum (60YO) or 
plasma (BiKE) using the same assays in all four studies. Similar for both studies, 
serum/plasma samples had been kept for several years in a large biobank frozen 
to -80 degrees Celsius until the measurements, underlying the biomarker data in 
this thesis, were performed. 
This phenomenon is not unusual in epidemiological biomarker research albeit 
has not been specifically investigated. If concentration levels were supposedly 
lower or higher due to long storage this would however lead to non-differential 
misclassification as neither the exposure (IL6 trans-signalling) or the outcome 
(CVE) would affect the degradation differentially. When compared to the exist-
ing literature, our results are in line with previous cytokine-based studies both in 
terms of direction and size of the association (148, 150-152). Furthermore, we do 
not aim to establish an absolute cut-off for any of the biomarkers studied.
The commercial assays used to analyse IL6, sIL6R and sgp130 do not discriminate 
between free and bound molecules. We have incorporated the individual compo-
nents of IL6 trans-signalling into the B/T ratio based on a previously described 
formula hence the proportion free vs. bound IL6 and sIL6R is not of interest. 
Moreover, in the analysis of serum and plasma sgp130 we could not discriminate 
between different isoforms of sgp130 albeit when we calculated the molar con-
centration of sgp130 we assumed a molecular weight of 100 kD (75), under the 
assumption that the most common form of circulating sgp130 is the full length, 
whose molecular weight is about 100 kD. In Study III, we have not calculated 
the B/T ratio since prospective data were not available to estimate the future risk 
of CVE in this population and we could not correlate the intra plaque B/T ratio 
with the circulating one.
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5.5.2.2 Gene expression analyses
In Study III, gene expression of IL6, IL6R, sIL6R, GP130 and sGP130 was ana-
lysed in carotid plaques extracted and cut in half during CEA with the one half 
(most proximal) being prepared by the BiKE group researchers for RNA analysis. 
When analysing expression in specific parts of the plaque there is a risk of missing 
receptors if there is an uneven distribution of receptors within the plaque. To over-
come this risk, the plaque can be homogenised which was not done in the present 
study. Another limitation is that inflammatory markers in the plaques could be 
affected by the surgery through which the plaque was obtained. This limitation is 
however impossible to overcome as all access to atherosclerotic plaques in living 
humans will entail a surgical procedure. Moreover, changes in the proportion of 
inflammatory cytokines within the plaque could take place after extraction from 
the vessel. To overcome this risk, plaques were immediately frozen to -80 degrees 
Celsius in connection to surgery.
Given the post-transcriptional modifications of the IL6R and GP130 genes, result-
ing in the sIL6R and sgp130 proteins, it would have been of great value to have 
done proteomics in carotid plaques instead of or in addition to transcriptomics. 
This limitation could result in differential misclassification as shedding is to a 
large extent driven by inflammation and patients with a recent plaque rupture 
would be expected to be subject to local inflammation in the carotid artery with 
increased frequency of shedding. Given that we saw significantly higher IL6R gene 
expression in plaques from symptomatic patients and that plasma levels of sIL6R 
decreased with time from cerebrovascular symptom to CEA this could imply that 
in the acute inflammatory context of a plaque rupture, shedding might increase 
circulating sIL6R and enabling IL6 trans-signalling. We did however want to ensure 
that the receptors quantified in the plaques were synthesised in the plaque and not 
up taken from the circulation and for this reason we decided to explore the gene 
expression in this first study of IL6 signalling in carotid plaques. 
With regards to sGP130 expression, only sGP130-RAPS was quantified as it is the 
sole sgp130 isoform verified by Western blot (94). Given that full length sgp130 is 
the most frequent circulating sgp130 isoform and in addition the most potent one 
this is a major limitation. Given our experimental design, we could not co-amplify 
more than two isoforms for each gene. For this reason, we chose the isoform whose 
transcription had been verified. In addition, the IL6 receptors were co-amplified 
in pairs (IL6R; sIL6R and GP130; sGP130) hence any potential differences in the 
expression levels between the membrane-bound (IL6R and GP130) and soluble 
receptor (sIL6R and sgp130) cannot be analysed. 
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Finally, we chose the average between the expression levels of two housekeeping 
genes to normalise our expression analysis. The reason underlying this choice 
was that we wanted at least two housekeeping genes given the complexity of the 
tissue analysed. 
5.5.2.3 Residual and unmeasured confounding
Increased levels of IL6 and its receptors could mirror other inflammatory condi-
tions that we have not analysed and hence could not adjust for. The population 
we analysed, was relatively homogenous being from the same generation living 
in the capital of Sweden, however other important factors such as socio-economic 
factors were not taken into account in this thesis. 
5.5.3 Misclassification of the outcome
All information of the outcome is derived from the Swedish national health 
 registers: The National Inpatient Register and the Cause of Death Register, using 
ICD-10 diagnosis codes, introduced in 1997 in Sweden. The positive predictive 
value of diagnoses in these registers is high and they are deemed reliable (196). As 
the National Inpatient Register does not include diagnoses from primary care we 
will have missed to categorise some individuals as cases (228). This is above all a 
problem when it comes to AF as MI and ischemic stroke in the absolute majority 
of cases will be cared for in hospitals. In Study IV, the secondary outcome was 
AF and we have accounted for the lack of primary care diagnoses by retrieving 
both main and secondary diagnoses of AF from the inpatient register. Another 
problem with retrieving diagnoses from registers is that some diagnoses such as 
AF often entail a delay in diagnostics due to subtle symptoms early in the course 
of the disease. There is hence a risk of misclassification of the outcome here and 
with that a possibility of underestimating the risk of AF associated with the B/T 
ratio, since a certain proportion of AF case would be falling in the referent group 
moving the HR towards 1. The same risk of diluting the association would however 
apply for IL6 which exhibited an association with AF. Possibly then either our 
findings correctly exclude an association of the B/T ratio with AF or the associa-
tion is weaker than that observed with IL6. 
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5.6 Conclusions
I  IL6 trans-signalling estimated by the binary/ternary complex ratio, the B/T 
ratio, is associated with the risk of future CVE in individuals without prevalent 
CVD.
II  The B/T ratio is associated with the risk of future CVE and early CVE primarily 
in individuals with a low-intermediate cardiovascular risk defined by LDL 
cholesterol or the Framingham Risk Score.
III  The genes of all components of the IL6 signalling pathways (IL6, IL6R, 
sIL6R, GP130, sGP130) are expressed in carotid artery plaques in patients 
with significant carotid artery stenosis.
IV The B/T ratio is associated with the risk of future atherothrombotic but not 
cardioembolic ischemic stroke. The B/T ratio is not associated with incident 
AF in individuals without prevalent or incident CVE.
5.7 Future perspectives
IL6 trans-signalling is associated with atherosclerosis progression and the clinical 
manifestations thereof. The CANTOS and COLCOT studies, demonstrated the need 
for inhibition of the IL1β-IL6-CRP pathway albeit with increased  serious adverse 
events most likely due to the concomitant inhibition of IL6 classical signalling 
and resulting deficient immune response (12, 215). Some researchers advocate 
moving upwards in the pathway, to antagonise the inflammasome (229). As seen 
in Figure 21, inhibiting the IL1β-IL6-CRP pathway upstream from IL6 trans-
signalling will however inevitably affect IL6 classical signalling. 
Apart from its relevance as biomarker of CVE risk, targeting the IL6 trans- signalling 
might thus represent a novel and safer therapeutic moiety. Compared to targeting 
IL6 or upstream of IL6, selective inhibition of IL6 trans-signalling is likely not to 
induce the observed adverse effects such as neutropenia and fatal infections (12, 
119, 215). 
Dampening IL6 trans-signalling with recombinant sgp130Fc has been shown to be 
effective in experimental mouse models of atherosclerosis and is currently tested 
in a randomised controlled trial in IBD (124). Given that the result is positive, the 
next step could be a randomised controlled trial of sgp130Fc in patients with stable 
CAD and/or ischemic stroke. To select suitable participants most likely to benefit 
from treatment, the B/T ratio could be used both as a marker of increased IL6 trans-
signalling and further, during treatment, as a biomarker to monitor treatment effects.
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6 SVENSK SAMMANFATTNING
Samspelet mellan cirkulerande inflammatoriska molekyler och kärlväggens celler 
orsakar en kronisk inflammation som leder till åderförkalkning (ateroskleros) med 
hjärninfarkt (stroke som orsakats av en propp) eller kranskärlssjukdom ledande 
till kärlkramp eller hjärtinfarkt som följd. En modern klinisk läkemedelsprövning 
visade nyligen att behandling med en antikropp som hämnar inflammationen vid 
ateroskleros minskar risken för nya hjärtkärlhändelser efter hjärtinfarkt. Man 
behöver dock utveckla nya metoder för att identifiera vilka patienter kan gynnas 
av en sådan anti-inflammatorisk behandling.
Syftet med denna avhandling är att undersöka om den inflammatoriska interleukin 
6 (IL6) trans-signaleringsvägen är associerad med ökad risk för hjärtkärl händelser 
(svår kärlkramp, hjärt- och hjärninfarkt) och i så fall om en markör för IL6 trans-
signalering kan användas för att predicera en ökad risk för hjärtkärlhändelser i 
framtiden hos individer utan känd hjärtkärlsjukdom samt att belysa IL6 trans-
signaleringens roll vid etablerad ateroskleros. 
I studie I, II och IV har vi använt oss av 60-års-kohorten, en studie där var tredje 
60-åring boendes i Stockholm 1997–1999 slumpvis utvaldes och tillfrågades om 
att medverka. Vid studiestart fick de 4232 deltagarna fylla i frågeformulär om livs-
stilsfaktorer, sjukdomar och läkemedelsbehandling. Blodprover togs vid studie-
start och med dessa har det aktiva binära IL6 komplexet och det inaktiva tertiära 
komplexet analyserats och sammanställts i en kvot, den så kallade B/T kvoten. I 
vår studie inkluderades endast hjärtkärlfriska studiedeltagare och dessa har sedan 
följts i svenska hälsoregister för att se vilka som insjuknat i hjärtkärlhändelser 
under uppföljningstiden (studie I-II t.o.m. 2014, studie IV t.o.m. 2017). 
I studie I undersökte om vi om B/T kvoten var associerad med risken för framtida 
hjärtkärlhändelser och kunde visa att deltagare som hade en hög B/T kvot, dvs en 
hög proportion av det aktiva binära komplexet i förhållande till det inaktiva tertiära 
komplexet, hade en ökad risk för framtida hjärtkärlhändelser.
I studie II ville vi undersöka om B/T kvoten var mer lämplig som markör i vissa 
grupper. Med tanke på att patienter som har en hög risk för framtida hjärkärl-
händelse av andra orsaker så som höga blodfetter eller många  hjärtkärlriskfaktorer 
får en grundlig genomgång och behandling ville vi undersöka om B/T kvoten kunde 
vara en lämplig markör för en ökad hjärtkärlrisk hos individer som inte hade en 
ökad risk värderat med de instrument vi har idag. Vi testade därför om B/T  kvoten 
var en lämplig markör hos de som hade låga-normala LDL-kolesterolnivåer eller 
de som med Framingham riskscore (internationellt validerat formulär för att mäta 
hjärtkärlrisk) hade förväntat låg risk för framtida hjärtkärlhändelser. Vi kunde visa 
att B/T kvoten var mer effektiv att predicera risk för hjärtkärlhändelser hos dem 
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som hade lågt LDL-kolesterol eller en förväntat låg hjärtkärlrisk med Framingham 
riskscore. Dessutom kunde vi i denna grupp av individer predicera tidiga hjärt-
kärlhändelser, framför allt hjärninfarkt. Vid test av interaktion kunde vi se att B/T 
kvoten och LDL-kolesterol inte verkade påverka risken tillsammans utan var för sig. 
I studie III ville vi undersöka om signalmolekylen IL6 och de receptorer som gör 
att IL6 kan påverka inflammationen i kärlen kunde hittas vid analys av gener i åder-
förkalkningsplack från förträngningar i halskärlen hos 78 patienter som opereras för 
denna förträngning. Vi analyserade gener i åderförkalkningsplacken tillsammans 
med nivåer av IL6 och dess receptorer i blodplasma i en kärlkirurgisk studie, the 
Biobank of Karolinska Endarterctomies (BiKE). Av de 78 patienterna hade 53 haft 
en hjärninfarkt eller TIA, dvs strokesymptom som gått över inom ett dygn, inom 
de senaste 6 månaderna. Åderförkalkningsplacken hos dessa  patienter betraktades 
som instabila om symptomen kunde stämma med att det var en propp från kärlet 
som orsakat hjärninfarkten/TIAn. Vi kunde se att IL6 och all dess receptorer fanns 
i åderförkalkningsplack i halskärlen på patienterna i BiKE studien. Vi såg också 
tecken till ökad mängd av de gener som ingår i det aktiva binära komplexet i plack 
hos patienter som haft en nylig hjärninfarkt/TIA.
Då vi i de föregående studierna sett att IL6 trans-signalering verkar vara associerat 
med hjärninfarkt och speciellt av den typen som beror på en propp från ett åder-
förkalkningsplack i ett förträngt halskärl så ville vi i studie IV undersöka om det 
också fanns en koppling till den typ av hjärninfarkt som orsakas av den vanliga 
hjärtrytmrubbningen, förmaksflimmer, känd för att kunna orsaka hjärninfarkt. Vi 
testade om B/T kvoten var associerad med risken för framtida hjärninfarkt hos 
individer med och utan känt förmaksflimmer i 60-års-kohorten och fann att B/T 
kvoten endast var associerad med hjärninfarkt hos individer utan förmaksflimmer. 
Vidare testade vi om B/T kvoten var associerad med förmaksflimret i sig men 
fann att den inte var det.
Slutsatsen av denna avhandling är att IL6 trans-signalering mätt med B/T kvoten 
är associerat med en ökad risk för framtida hjärtkärlhändelser och att B/T kvoten 
därför kan användas som markör för ökad risk framför allt hos individer som 
bedöms ha en låg risk med nuvarande prognosinstrument. Vidare är B/T kvoten en 
god prediktor för framtida hjärninfarkt men verkar inte kunna predicera risken för 
hjärninfarkt orsakad av förmaksflimmer eller risken för förmaksflimmer ensamt.
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